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Delivering ocular therapeutics to a target site with minimal side effects  
requires detailed information about the distribution and elimination pathways.  This 
knowledge can guide the development of new drug delivery devices.  In this study, 
we investigated the movement of two drug surrogates, H-110, which is lipophilic, and 
Gd-DTPA, which is hydrophilic, released from polymer-based implants using a 
fluorescein technique and magnetic resonance imaging (MRI).  We also studied the 
pharmacokinetics of intravitreally injected triamcinolone acetonide, a low water 
soluble drug used for treating sight-threatening diseases such as diabetic retinopathy 
and choroidal neovascularization associated with age-related macular degeneration 
(AMD). 
At 24 hour post implantation, H-110 released from an intravitreal implant  
  
was detected in the subretinal space.  However, following a subconjunctival implant, 
very little H-110 fluorescence was detected in the subretinal region.  H-110 most 
likely reached the subretinal space from an intravitreal implant by diffusion through 
the vitreous and retina.  However, most of the H-110 released from a subconjunctival 
implant is thought to dissipate through the choroidal blood flow. 
Concentration profiles of Gd-DTPA, which was released from an intravitreal  
implant in a New Zealand white rabbit, approached pseudo-steady state within 7 to 8 
hours and showed gradients at the rabbit’s vitreous-retina border suggesting that 
diffusion was occurring into the retinal-choroidal-scleral membrane.  Parametric 
analysis with a finite element mathematical model of the rabbit eye yielded for Gd-
DTPA a diffusion coefficient of 2.8 × 10-6 cm2/sec in the vitreous and a permeability 
of 1.0 × 10-5 cm/sec in the composite retina-choroid-sclera membrane.  Gd-DTPA 
concentration decreased away from the implant.  Such regional concentration 
variations throughout the vitreous may have clinical significance when the ubiquitous 
eye diseases are treated using a single positional implant.  Subconjunctival implants 
in vivo delivered a mean total of 2.7 µg of Gd-DTPA over 8 hours into the vitreous 
representing only 0.12% of the total amount of compound released from the implant 
in vitro.  No Gd-DTPA was detected in the posterior segment of the eye.  Ex vivo, the 
Gd-DTPA concentration in the vitreous was 30 fold higher suggesting the elimination 
of significant in vivo barriers to the movement of drugs from the subconjunctival 
space into the vitreous. 
We developed a new preservative-free formulation for intravitreal injections  
  
of triamcinolone acetonide for the treatment of diabetic macular edema, and choroidal 
neovascularization associated with AMD in human clinical trials at the National 
Institutes of Health.  A pharmacokinetic study in rabbits was done to estimate 
elimination rate of two injection amounts of triamcinolone acetonide, 4 mg and 16 
mg, from the vitreous.  From our pharmacokinetic model, we found the half-lives for 
4 mg and 16 mg injection in the vitreous to be 18.6 days and 37.6 days, respectively.  
We subsequently estimated the half-lives of 1 mg and 8 mg triamcinolone acetonide 
injection in order to predict therapeutic exposure in human. 
There are three components in this thesis: the study of lipophilic H-110  
transport with fluorescence, the study of hydrophilic transport of Gd-DTPA with 
MRI, and the pharmacokinetic analysis of triamcinolone acetonide.  They have each 
contributed to further insights into our fundamental understanding of drug movement 
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CHAPTER 1. Introduction 
 
1.1 Background and Motivation 
 
1.1.1. Structure of the eye 
The structure of the eye can be depicted with three different layers:  
external layer (cornea and sclera), intermediate layer (iris-ciliary body and choroid), 
and internal layer (retina) [1].  The eye is filled with two kinds of fluids: aqueous 
humor between the cornea and the iris and vitreous humor between the lens and retina 
(Figure 1-1).  
The cornea is an optically transparent tissue that allows light to reach  
the retina.  This tissue is non-vascular, and nutrients and oxygen are supplied by 
diffusion from lachrimal fluid and aqueous humor as well as from blood vessels 
located at the junction between the cornea and the sclera.  The tissue is approximately 
0.5 mm thick in the central region and 0.7 mm at the peripheral region.  The cornea is 
composed of five layers of tissues: epithelium, Bowman’s membrane, stroma, 
Decement’s membrane, and endothelium [2].  The epithelium has tight junctions and 
is a hydrophobic layer, which makes it a dominant important barrier to drug delivery.  
The Bowman’s membrane separates the epithelium and the stroma.  The stroma 
comprises 90% of the corneal thickness.  This region is hydrophilic because 85% of 
the stroma is water.  The Decement’s membrane lies between the stroma and the 

















controlling corneal hydration.  To deliver therapeutic agents into the eye through the 
cornea using topical eye drops, drug carriers must possess both hydrophilic and 
lipophilic properties and be sufficiently small to pass through tight junctions. 
The sclera forms about five-sixth area of the outer envelope of the eye  
[3].  The sclera is a fibrous tissue extending from the cornea to the optic nerve.  It is 
usually referred to as the “white of the eye” and is a protective layer.  About 70 % of 
the sclera is water, and the remaining components are mainly fibrillar collagen 
(predominately collagen type I) and proteoglycans containing glycosaminoglycan 
side chain [3]. 
The iris is the colored part of the eye and controls light entering eye.   
The iris divides the anterior humor chamber from the posterior humor chamber.  The 
ciliary body produces the aqueous humor at rate of 2.2 × 10-3 ml/min [4].  1-2% of 
aqueous humor production flows in the posterior direction into the vitreous [5] and 
the remaining flows in the anterior direction and drains through the Schlemm’s canal.  
 The choroid is vascular and pigmented tissue between the retina and  
the sclera.  The retinal pigment epithelium (RPE) is located between the choroid and 
the retina and the superchoroidal space is between the choroid and the sclera.  The 
choroid is composed of layers of blood vessels that nourish the subretinal region.  
The retina is a multi-layered membrane occupying the internal space  
of the posterior portion of the eye wall (Figure 1-2).  One side of the retina contains 
the rod and cones and is adjacent to the retinal pigment epithelium (RPE) and the 
choroid; the other side of the retina faces the vitreous.  Photoreceptor cells are located 



















that serves fine central vision and color perception. The fovea is a depression at the 
center of macula. 
The vitreous is a transparent substance that fills the center of the eye  
between the lens and the retina.  It is composed of hyaluronic acid and collegn [6] in 
98% water.  Aqueous humor is the water fluid that fills the space between the  
cornea and the iris.  It is continually produced by the ciliary body at a rate of  
2.2 × 10-3 ml/min [4].  This fluid nourishes the cornea and the lens. 
 
1.1.2. Ocular diseases 
Millions of people suffer from various ocular diseases, many of which  
lead to irreversible blindness.  Table 1-1 shows statistics about the number of people 
suffering from ocular diseases [7].  The number is increasing as the worldwide 
population continues to age.  Among ocular diseases, the posterior segment ocular 
diseases, AMD, diabetic retinopathy, and glaucoma, are the main causes of 
irreversible blindness in developed countries.  Studies have been aimed at developing 
treatments of these diseases [8-12].  However, only few therapeutic agents for the 
posterior segment ocular diseases have been commercialized [13].  Table 1-2 shows 
pharmacological agents for retinal diseases in ongoing clinical trials.  
Choroidal neovascularization (CNV) is associated with AMD.  Several  
treatments are available to treat CNV including photodynamic therapy, radiotherapy, 
and transpupillary thermotherapy [14].  The initial successful results that patients may 
experience with these treatments are frequently lost with recurrent CNV.  As a result, 
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pharmacologic approaches are being developed using anti-angiogenic agents to treat 
CNV.  However, adequate drug delivery systems to treat CNV are lacking.  
 
Table 1-1. Ocular diseases and number of patients 
 
Disease Number of patients 
Cataract 6 – 19% of patients over 43 years of age 
Age-related macular degeneration 11 – 28% of patients over 65 years of age 
Glaucoma 1 – 4% of patients over 45 years of age 
Diabetic retinopathy 71 – 90% diabetics over 10 years of age 
Dry eye (US) 50 – 60 million (~ 10 – 15% of US population) 
Ocular allergy ~ 25% of US population 







Table 1-2. Pharmacological agents for retinal diseases. 
 
Drug class Drug Disease injection 
Photodynamic therapy Visudyne AMD CNV[11] 
PKC-β inhibitor Ruboxistaurin, 
 Mesylate (LY333531) 
DME, DR[50, 51] 




Angiostatic cortisense Anecortave acetate (AL-3789) AMD CNV[53] 
Glucocorticoid Fluocinolone acetonide 
Triamcinolone acetonide 
DME, uveitis [54] 
DME, AMD CNV [18] 
 
Note: AMD CNV: age-related macular degeneration – associated choroidal        
Neovascularization; DME: diabetic macular edema; DR: diabetic retinopathy; PME: 
persistent macular oedema; RhuFab: recombinant human antibody fragment; VEGF: 
vascular endothelial growth factor 
 
 
1.1.3. Ocular drug delivery 
Ocular therapeutic agents can be delivered to a target site by several  
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types of drug delivery methods (Figure 1-3).  Methods of ocular drug delivery in 
Figure 1-3 are roughly categorized into three methods: topical administration, 
injection, and sustained-release implant.  
Systemic administration of therapeutic agents has been used for the  
treatment of ocular diseases.  However, only 1 – 2% of plasma drug concentration 
reaches the vitreous cavity [1].  To achieve a therapeutic drug level in the eye, 
frequent systemic administration with high drug doses are required which may induce 
systemic side effects.   
Ocular drug delivery by topical administration such as eye drops  
accounts for nearly 90% of ocular therapeutic formulations [15].  It has been reported 
that less than 5% of a topically applied drug permeates the cornea because of physical 
properties of the cornea, and tear washout [16].  Few topically applied drugs can 
reach the posterior segment of the eye because of the long diffusion distance and the 
rapid clearance by aqueous humor flow. 
Directly injecting drugs into the vitreous [17-19] or placing an  
intravitreal sustained release device (Figure 2 (G) and (F)) [20-22] have shown 
favorable results at delivering therapeutic agents to the posterior segment of the eye 
in clinical trials.  However, some complications such as vitreous hemorrhage, retinal 















Since an intravitreal injection and intravitreal implants can produce  
complications, and since many of the posterior segment ocular diseases are chronic 
and require delivery of ocular agents for extended time periods, many researchers 
have investigated the use of transscleral drug release devices.  In in vitro studies, it 
has been found that drugs with a molecular weight up to 150 kDa can diffuse through 
the sclera [3, 25, 26].  In in vivo studies, subconjunctivally applied drugs were 
detected in the retina and in the vitreous [27-30].  Table 1-3 lists several implant 
devices that have been studied as alternative sustained delivery methods.  However, at 
this time, only a few intravitreal vitreous ocular implants have been commercialized, 
















Table 1-3. Summary of Sustained release ocular implants. 
 
Implant Material Model drug Property Ref. 
POE 5-fluorouracil bioerodible [55] Subconjunctival 
implant 
PVA cytochalasin E biocompatible [56] 
PLGA ganciclovir biodegradable [57] 












PLA Budesonide biodegradable [60] 











Note: POE: poly(ortho ester); PVA: poly(vinyl alcohol); PLGA: poly (lactic-glycolic 
acid); poly(lactic acid) 
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1.1.4. MRI in the ocular research 
MRI, magnetic resonance imaging, can produce images of internal  
regions of the body based on the principles of nuclear magnetic resonance.  When an 
experimental object is placed in a strong electromagnetic field, hydrogen atoms in the 
object align themselves parallel with the magnetic field, either in the same direction 
or opposite to the direction of the field depending on magnetic charge.  At pre-
determined slice through the object, a short radio frequency signal (RF) is sent 
through the experimental object, perpendicular to the main magnetic field.  The 
hydrogen atoms, which have the same frequency as the RF, become excited and 
resonate with the excitation wave.  When the RF is turned off, the hydrogen atoms 
return to their original energy state.  The excited energy is released in the form of 
radio waves, which are detected by antenna coils in the MRI machine.  The time it 
takes for the excited hydrogen atoms to return to their original energy level depends 
on the number of atoms and characteristic physical properties of the various tissue 
types.  This time is measured and analyzed by a computer.  These measurements are 
used to construct images of tissues of the experimental object.  MRI has been used 
widely in investigations of the eye such as determining anatomy and pathology [31-
33], following movement of the aqueous humor [34-36], detecting blood retinal 
barrier breakdown [37] or preretinal neovascularization in diabetic retinopathy [38], 
and detecting the effect of vascular endothelial growth factor (VEGF) [39].  
The concentration distribution and clearance of a MRI contrast agent,  
Gd-DTPA delivered to the rabbit eye by subconjunctival and intraocular (injections 





Pharmacokinetics, which describes the quantitative relationship  
between administered dose and tissue concentration over time, is an important tool in 
drug development.   Worakul et al. [40] reviewed various ocular pharmacokinetic 
models for drug delivery systems to the front of the eye, but not to the posterior 
segment of the eye.  Currently, the two available clinical methods to deliver ocular 
therapeutic agents to the deep eye structures are direct injections into the vitreous and 
intravitreal placement of sustained release implants.  To optimize drug concentration 
at the target sites, pharmacokinetic studies are useful.  Several studies have 
investigated the elimination of applied drugs in the vitreous with compartmental 
models [41, 42].  Both the vitreous and the aqueous humor were represented by 
homogenous compartments and the elimination rate constant and the half-lives were 
determined.  One of assumptions of lumped compartmental analysis is that model 
drug distributes homogeneously throughout each compartment [43].  Therefore, a 
limitation of the compartmental pharmacokinetics is that the spatial distribution of an 
applied drug within the region of interest such as the vitreous is not obtained.  We 
used pharmacokinetic compartment models to analyze our Gd-DTPA data and 
triamcinolone acetonide data.  To overcome the limitation of the compartmental 
pharmacokinetics, several studies have been done to determine the disposition of 
ocular drug injected or released from an intravitreal implant in the vitreous using 
finite element mathematical models of the eye [4, 44-49].  
We have developed such a finite element model and compared our  
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experimental MRI data for Gd-DTPA to the simulations in order to estimate several 
transport parameter values such as retinal permeability.  In addition, we simulated the 
distribution of model drug in the vitreous and the posterior segment of the eye. 
 
1.2 Research objectives 
Our general research objectives were to develop new drug delivery  
methods and optimize the delivery of therapeutic agents to a specific target site, in 
this case, the posterior segment of the eye.  To achieve this goal, it is necessary to 
understand the movement and the elimination of therapeutic agents injected or 
released from a sustained release implant. To this end, the following studies have 
been done: 
(1) Investigate the distribution of fluorescein conjugated lipophilic material 
released from either a subconjunctival implant or an intravitreal implant in 
the Brown-Norway rat eye in Chapter 2. 
(2) Study the 3-D dynamic movement of drug surrogate, Gd-DTPA released 
from either a subconjunctival implant or an intravitreal implant in the 
rabbit eye with a MRI technique in Chapter 3. 
(3) Develope a finite element mathematical eye model to analyze the MRI 
experimental data quantitatively by comparing the data to simulations in 
Chapter 4 and 5. 
(4) Study the pharmacokinetics of intravitreal administration of a 
triamcinolone acetonide preservative-free (TAC-PF) formulation in the 
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rabbit eye to determine obtain a model of drug residence time that could 
be extrapolated to human trials in Chapter 6. 
 
To accomplish these goals, it was necessary to develop a sustained release  
implant device for both intravitreal and subconjunctival placement.  We developed 
implants of polyvinyl alcohol (PVA) or hydroxypropyl methyl cellulose (HPMC) to 



















CHAPTER 2. Movement of H-110 in the eye 
 
2.1 Objectives 
The movement of a small size and lipophilic agent released from  




Previous studies have been performed to aid in the understanding of 
 the movement of drugs injected intravitreally or subconjunctivally in the eye [62-64].  
Also, simulations have been done to predict the distribution of ocular drugs in the eye 
[4, 44].  However, most of these previous studies have related to the movement of 
hydrophilic fluorescein or fluorescein-conjugates. 
A limited number of studies [56, 65, 66] have been done that delivered   
lipophilic anti-angiogenic therapeutics to the subretinal region and the retina pigment 
epithelium (RPE) with sustained release technology.  These studies are relevant since 
one of factors affecting the movement of administered drugs is solubility and many 
anti-angiogenic agents are lipophilic. 
In this study, we determined the distribution of a small size and  
lipophilic agent, 5-hexadecanoylaminofluorescein (H-110), released from a polyvinyl 
alcohol (PVA) based implant or a hydroxypropyl methyl cellulose (HPMC) based 




2.3 Materials and methods 
2.3.1 Materials 
5-hexadecanoylaminofluorescein was purchased from  
Molecular Probes (Eugene, OR, USA).  Polyvinyl alcohol (AIRVOL® 125, 99.48 mol 
% hydrolysis) was purchased from Air Products and Chemicals (Allentown, PA, 
USA).  Hydroxypropyl methyl cellulose (HPMC) was purchased from Sigma (St. 
Louis, MO, USA).  
 
2.3.2 Implants fabrication 
Two types of sustained release matrix implants were fabricated  
by mixing the model compound, H-110 (MW = 586) with either polyvinyl alcohol 
(PVA) (implant A) or hydroxypropyl methyl cellulose (HPMC) (implant B).  Both 
implants A and B were 1.5 mm flat discs, making them suitable for insertion into the 
vitreous and the subconjunctival space of a rat eye.  Both implants were prepared 
using the following procedure: a 15% polyvinyl alcohol (PVA) (w/v) solution was 
prepared by placing 0.75 g of PVA in 5 ml of molecular biology grade water 
(Eppendorf Scientific, Inc., Westbury, NY, USA) in a closed vial, and placed in a 
waterbath at 100 ºC for 3 hours. A 30% H-110 matrix suspension was produced by 
adding 0.321 g of H-110 to the PVA solution.  The drug suspension was stirred until 
uniform and poured onto a glass plate to form a thin film and dried at room 
temperature in the dark.  The film was punched with a biopsy punch (Acu·Punch® 1.5 
mm, Acuderm, USA) to make 1.5 mm diameter disks.  
Comparable 30% H-110 implants were made in a similar fashion using 15%  
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HPMC instead of PVA. Sham implants (implants without H-110), of 15% PVA or 
15% HPMC, were also made. 
 
2.3.3 In vitro study 
In vitro release rate experiments were performed on the 15% PVA / 
30% H-110 for 7 days and the 15% HPMC / 30% H-110 for 5 hours.  Implants were 
placed in 20 ml of phosphate buffered saline (PBS) (pH 7.4) and stirred slowly with a 
magnetic stirrer.  The solution was assayed at designated time intervals and 
completely replaced with fresh PBS at each sampling time to maintain sink condition.  
H-110 assays were performed using a spectrofluorometer (QuantaMaster, Photon 
Technology International, Lawrenceville, NJ) at excitation wavelength 497 nm and 
emission wavelength 519 nm.  The release rates were determined from the amount of 
H-110 released over time and recorded as µg per day. 
 
2.3.4 Animal experiment 
All animal care conformed with the ARVO Statement for the Use of  
Animals in Ophthalmic and Vision Research and was approved by the Animal Care 
and Use Committee at the National Eye Institute.  Before surgeries, the rats were 
anesthetized by intraperitoneal injection of a mixture of ketamine (100 mg/kg) and 
xylazine (9 mg/kg).  The implants were surgically placed in the subconjunctival space 
or the vitreous cavity of Brown Norway rats.  The HPMC based implants or the PVA 
based implants were placed in the subconjunctival space and the animals were 
sacrificed at 1, 2, 3, and 4.5 hours post implantation or at 3, 5, and 7 days post 
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implantation, respectively.  Only HPMC based implants were placed in the vitreous 
cavities and the animals were sacrificed at 1, 2, 3, and 24 hours post implantation. 
 
2.4 Results 
2.4.1 In vitro release rates 
Fifteen% PVA / 30% H-110 implants (n=4) released H-110 over 7  
days following an initial bursts (Figure 2-1 (A)).  On the other hand, 15% HPMC / 
30% H-110 implants (n=4) released most of its contents of H-110 within the first 1 
hour sample time.  HPMC is a very water-soluble material and disintegrates quit 
rapidly in water (Figure 2-1 (B)).  A HPMC-based implant shows a time release 









































                                 (A)                                                                       (B) 
Figure 2-1. In vitro release rate of H-110 from (A) 15% PVA / 30% H-110 implant 




2.4.2 Distribution of H-110 released from subconjunctival implants 
Figure 2-2 are frozen section tissue slices showing the position of  
implants in the subconjunctival space for: (A) the PVA based subconjunctival implant 
in the posterior segment of the eye and (B) the HPMC based subconjunctival implant.  
Since the HPMC based implant dissolved quickly, its outline is not as readily visible 
as the PVA based implant.  Figure 2-3 (A) shows the fluorescence intensity in a tissue 
slice 3 days after the subconjunctival implantation of a PVA implant.  H-110 is seen 
to be distributed in the subconjunctival space and the sclera which can be compared 
to the sham implant in Figure 2-3 (B).  In Figure 2-3 (A), the black rectangle 
designates the position of the implant in the subconjunctival space.  A small amount 
of H-110 was found in the subretinal region; but is much less than that found in the 
sclera.  Figure 2-4 and 2-5 show serial frozen sections of eye tissue at different 
magnification.  We can see that a small amount of H-110 released from an HPMC-
based subconjunctival implant reaches the subretinal from a PVA-based 
subconjunctival implant (Figure 2-4).  This may result from the more rapid release of 
H-110 from the HPMC implant compared to the PVA implant.  These findings 
suggest that there might be a formidable barrier such as the choroid, between the 
retina and the sclera. 
Figure 2-6 presents an interesting finding that the HPMC-based  
subconjunctival implant distributes around the circumference of the sclera as quickly 
as 4.5 hours post implantation.  This distribution of H-110 is faster than would be 
expected from only pure diffusion.  Additional mechanisms of H-110 movement may 
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be in play, such as uveal-scleral flow [64] and enhance the distribution.  Investigation 
of the possible mechanism was beyond the range of this study. 
 
(A)                                                            (B)   
 
Figure 2-2. (A) The position of the PVA-based subconjunctival implant at the 





























                                                               (B) 
Figure 2-3. Florescence intensity distribution of H-110 in tissue slice 3 days post 
implantation in the sclera, the choroids, and retina regions; (A) a 15% PVA / 30% H-







Figure 2-4. Distribution of H-110 released from a 15% PVA / 30% H-110 
subconjunctival implant 3 days post implantation. The right image (×20 



























Figure 2-5. Distribution of H-110 released from a 15% HPMC / 30% H-110 implant 3 










Figure 2-6. Distribution of H-110 released from a 15% PVA / 30% H-110 implant in 









2.4.3 Distribution of H-110 released from intravitreal implants 
Delivering therapeutic agents from the vitreous is an alternative  
delivery route to the subretinal region in the posterior segment of the eye.  To date, 
only the intravitreal implants among several sustained release implants have been 
commercialized [13].  We used an HPMC based implant to release H-110 into the 
vitreous cavity.  Figure 2-7, 2-8, and 2-9 show the distribution of H-110 released 
from the intravitreal implant in the posterior segment of the eye, specially, in the 
retina.  With time, we could see the penetration of released H-110 into the retina.  H-
110 diffused by the inner segments layer and by the outer plexiform layer in the retina 
1 hour and 3 hours post implantation (Figure 2-7 and 2-8), respectively.  After 1 day, 
H-110 was found in the subretinal region (Figure 2-9).   
Compared to the subconjunctival experimental data, delivery of   
lipophilic agents from the vitreous to the subretinal region was found to be more 
































Figure 2-7. (A) Distribution of H-110 released from a 15% HPMC / 30% H-110 
intravitreal implant 1hour post implantation (×10 magnification). (B) The control 















Figure 2-8. (A) Distribution of H-110 released from a 15% HPMC / 30% H-110 
intravitreal implant 3 hours post implantation (×10 magnification). (B) The control 


















Figure 2-9. Distribution of H-110 released from a 15% HPMC / 30% H-110 










Recent studies have suggested that lipophilic therapeutic agents are 
useful for treating a variety of subretinal disorders such as AMD in experimental 
animal models [28, 54, 60, 65].  According to clinical reports, corticosteriods such as 
budesonide and triamcinolone acetonide, which are lipophilic agents, have shown 
reasonable results in treating choroidal neovascularization associated with AMD [9, 
67-69], diabetic retinopathy [19, 70] and macular edema associated with central 
retinal vein occlusion [71-73].  However, the fate of a lipophilic agent in the eye after 
administration is uncertain.  Weijtens et al. (1999) injected 2.5 mg of dexamethasone, 
which is lipophilic, in the subconjunctival space and measured drug concentration in 
the aqueous humor and the vitreous at several time points.  The maximum 
dexamethasone concentration in the aqueous and in the vitreous was 858 ng/ml in the 
vitreous at 2.5 hours post injection and 72.5 ng/ml in the aqueous at 3 hours post 
injection [28].  Only a small fraction of the injected dexamethasone was delivered to 
the eye tissue.  In this study, it appeared difficult to deliver lipophilic and small size 
ocular drugs from the subconjunctival space to the subretinal region because of the 
formidable barriers such as the choroidal blood flow washout. 
In  previous animal experiments, PVA-based intravitreal implants  
showed some delivery of 2-methoxyestradiol to the posterior sub-retinal tissue.  
Robinson et al. [65] developed an intravitreal implant that released 2-
methoxyestradiol and it was able to inhibit CNV in an animal model compared to the 
control.  However, because of the complications of intravitreal implants, 
subconjunctival implants is an attractive alternative (See Table 1-3).  Kim et al. 
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(2002) [63] investigated the intraocular distribution kinetics of 70 kDa fluorescein-
conjugated dextran after subconjunctival injection in the rat eye.  The fluorescein-
conjugated dextran diffused transsclerally and dispersed throughout a large portion of 
the sclera, uvea, and cornea through the uveoscleral outflow pathways. Transscleral 
influx and intrachoroidal dispersion of 70 kDa fluorescein-conjugated dextran in the 
mouse eye was not precluded by either transcleral aqueous flow or by choroidal blood 
flow.  In our study, H-110, a lipophilic agent, dispersed around the circumference of 
the eye (Figure 2-6) in the similar fashion as the fluorescein-conjugated dextran.  H-
110 reached the opposite pole of the eye 4.5 hours post implantation.  Pure diffusion 
of H-110 alone cannot account for this distance at 4.5 hours.  Therefore, a uveoscleral 
outflow mechanism may enhance the H-110 dispersion around the eye as in the case 
of fluorescein-conjugated dextran.  Unlike fluorescein-conjugated dextran, little H-
110 could reach the subretinal space.  The choroidal blood flow was found to be a 
more formidable barrier to lipophilic and small size agents than hydrophilic and large 
size agents.  However, in this study, we did not determine whether solubility or 
molecular size was the main factor in the elimination through the choroid.  
In the in vivo implant studies, we found that it was more efficient to  
deliver H-110 from the vitreous to the subretinal space than from the subconjunctival 
to the retina.  In our study, H-110 diffused into the retina uniformly (See Figure 2-7, 
2-8 & 2-9).  A previous study found that intravitreally injected fluorescein, which is 
hydrophilic, was eliminated across the retina by the active transport [62].  Based on 
the previous study, we assumed H-110 moved into the retina mainly by pure diffusion 
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because the retina is lipophilic and the retina was not a barrier to the delivery of H-
110 to the subretinal space [46]. 
Our polyvinyl alcohol (PVA) based subconjunctival implant showed  
sustained release of H-110 for over one week following the initial rapid release.  PVA 
has been our preferred choice for ocular implants because of its biocompability [65].  
The initial rapid release might be due to the H-110 on the surface of the implant 
because H-110 might have diffused onto the surface with the water vapor during the 
drying process in the implant fabrication [74]. 
 
2.6 Conclusions 
Delivering small size and lipophilic agents from the vitreous to the subretinal  
region was found to be more efficient than delivering from the subconjunctival space 
to the subretinal region because the choroid was a formidable barrier to the passage of 
a lipophilic fluorescent compound released from a sustained release device placed in 











CHAPTER 3. Controlled drug release from an ocular implant: 
real-time evaluation using magnetic resonance imaging 
 
3.1 Objectives 
The movement of small size and hydrophilic agents released from sustained  




Standard preclinical techniques of assessing ocular drug distribution,  
autoradiography and fluorescein labeling require euthanasia of different animals at 
variable time points with serial sectioning of the eye to reenact the movement of the 
drug molecules in vivo [75].  Standard techniques do not permit time serial studies 
and determination of drug diffusion gradients in the eye of individual animals.  
Fluorophotometry is limited to assessments of bulk fluorescein movement in the 
aqueous and vitreous humor [76].   
In this chapter, we sought to develop a technique to evaluate the ocular  
distribution and elimination pathways of a drug surrogate from a sustained-release 
implant in normal rabbit eyes using magnetic resonance imaging (MRI) technology.  
We developed a sustained-release implant that releases the contrast agent gadolinium-
diethylenetriaminopentaacetic acid (Gd-DTPA, molecular weight = 938 Daltons).  
These implants were evaluated separately in the subconjunctival space on the 
 33 
 
episclera at the equator and in the vitreous cavity.  Real-time movement of the drug 
surrogate was assessed with MRI. 
 
3.3 Materials and methods 
3.3.1 Implant fabrication 
An episcleral implant was manufactured using the procedure as shown  
in Figure 3-1: 10% polyvinyl alcohol (PVA) (w/v) solution was formulated by 
placing 1.0 g of PVA (Celvol, Celanese Chemicals, Ltd., Dallas, TX) in 10 ml of 
molecular biology grade water (BIOfluids®, Biosource International, Camarillo, CA) 
in a 50 ml polypropylene conical tube (Falcon®, BD Biosciences, Franklin Lakes, NJ) 
and placed in a water bath at 100°C for 3 hours to dissolve all the PVA.  The PVA 
solution was cooled down to room temperature and 0.71 ml of 0.5 M Gd-DTPA 
solution was added and stirred into the PVA mixture to produce a solution of 10% 
PVA and 25% Gd-DTPA (w/w/v).  Eight ml was poured onto a glass plate which 
produced a thin film as it dried at room temperature.  A biopsy punch (Acu•Punch 4 
mm, Acuderm Inc, Ft. Lauderdale, FL) was used on the dried film to make 4 mm 
diameter disks.  Individual disks (8 total) were placed in a polytetrafluoroethylene 
mold, which has a 4.3 mm diameter and a 1.4 mm depth.  The disks were coated with 
the remaining 10% PVA and 25% Gd-DTPA (w/w/v) solution.  The dried implant 
was peeled out of the polytetrafluoroethylene mold and a total of 6.4 mg of Gd-DTPA 
was loaded into each episcleral implant.   
An intravitreal implant was manufactured in a similar fashion as above  
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except less drug loading per implant was necessary to decrease the intensity of the 
Gd-DTPA signal in the vitreous (Figure 3-2).  To accomplish this, a 15% PVA and 
20% Gd-DTPA (w/w/v) solution was substituted and a smaller implant was made 
with 3 mm disks and mold dimensions of 3.2 mm diameter and 1.2 mm depth with a 
suture stub extension on one side of the implant for scleral fixation.  A total of 3.7 mg 






Figure 3-1. Fabrication procedure for the episcleral implant. 1: PVA/Gd-DTPA 
solution in mold   2:  PVA/Gd-DTPA dry matrix discs inserted  3: complex cured  4: 
schematic of implant removed from the mold with dimensions  5:  Photograph of the 







Figure 3-2. Fabrication procedure for the intravitreal implant. 1: PVA/Gd-DTPA 
solution in mold   2:  PVA/Gd-DTPA dry matrix discs inserted  3: complex cured  4: 
schematic of implant removed from the mold with dimensions  5:  Photograph of the 
Gd-DTPA intravitreal implant. 
 
3.3.2 In vitro release rate determination  
As previously reported [77], the release of Gd-DTPA from both  
the episcleral and intravitreal implants was equal from all external surfaces except at 
the suture platform in the intravitreal implant.  For the batch of implants used in this 
study, bulk release was determined by placing the implants in 25 ml glass vials with 
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20 ml of phosphate buffered saline (PBS) (pH 7.4) and stirred with a magnetic bar at 
150 rpm at room temperature.  The solution was assayed every 10 minutes for one 
hour, every 30 minutes for the second hour, and hourly for the next 6 hours.  The 
solution was completely replaced following each assay with fresh PBS to simulate 
sink conditions.  The Gd-DTPA assays were performed using a spectrofluorometer 
(QuantaMaster, Photon Technology International, Lawrenceville, NJ) operated by 
FeliX (version 1.21, Photon Technology International).  A calibration curve was 
made using a 275 nm excitation wavelength and a 312 nm emission wavelength and 
the lowest detectable concentration of Gd-DTPA was 4.69 ng/ml.  The release rates 
were determined by calculating the amount of Gd-DTPA released in a given volume 
over time and recorded in mg per hour ± 1 S.D.   
 
3.3.3 Magnetic resonance imaging  
Dynamic MRI was used to image the rabbit eyes.  All imaging experiments  
were performed on a 4.7 Tesla MRI system (Bruker Instruments, Billerica, MA).  The 
images were analyzed using MATLAB (version 6.5, Mathworks Inc., Natick, MA) 
and Amira (version 2.3, TGS Inc., San Diego, CA).   
 
3.3.3.1 In vivo experiments 
 
New Zealand White (NZW) rabbits (n=3) weighing 2-3 kg were used  
(Covance Laboratories, Inc., Vienna, VA) and the procedures adhered to the 
guidelines from the Association for Research in Vision and Ophthalmology for 
animal use in research.  Each rabbit was maintained under general anesthesia during 
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the 8-hour imaging period.  The animals were initially anesthetized with ketamine 
hydrochloride (Fort Dodge, Inc., Fort Dodge, Indiana) 35 mg/kg intramuscular (IM) 
and xylazine (Phoenix Scientific, Inc., St. Joseph, MO) 5 mg/kg IM and an 
intravenous catheter was inserted into the marginal ear vein to administer fluids.  An 
endotracheal tube was placed and anesthesia was maintained with 1 to 2% halothane 
or 1 to 2% isoflurane.  During anesthesia, the rabbit’s pulse, SpO2, end-tidal CO2, 
respiratory rate, anesthetic gas levels, and body temperature were monitored and 
maintained via a water pad connected to a heated recirculating pump.  After adequate 
anesthesia and akinesia were obtained, a lid speculum was placed and the right pupil 
was dilated with 1 drop of phenylephrine hydrochloride 2.5% (Akorn, Inc., Decatur, 
IL) and tropicamide 1% (Alcon, Inc., Humacao, Puerto Rico).  Proparacaine 1% 
ophthalmic drops (Allergan America, Hormigueros, PR) were used topically on the 
eye and an incision was made through the conjunctiva and tenon’s fascia in the 
superotemporal quadrant at the equator of the globe.  The equator of the rabbit eye 
was defined as the point at which the sclera starts the downward slope towards the 
optic nerve, approximately 5-6 mm posterior to the limbus.[78]  The episcleral 
implant was placed directly on the episclera at the equator and the tenon’s fascia and 
conjunctiva was reapproximated using 8-0 vicryl suture.  For intravitreal placement, a 
4 mm sclerotomy was performed at the equator, the implant was inserted into the 
vitreous cavity and sutured to the sclera using 8-0 vicryl suture.  The sclerotomy was 
closed using 8-0 vicryl suture and the conjunctiva was reapproximated to the limbus 
using 10-0 vicryl suture.  The rabbit was positioned in the scanner and the head was 
centered in a 10 cm diameter volume coil and imaged for 8 hours.  Complete T1- 
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weighted Fast Spin Echo 3D images were acquired over 20 minute intervals.  The 
imaging parameters were Repetition time (TR)/ echo time (TE) = 267/9 ms, Field of 
View (FOV) = 9 cm × 9 cm × 9 cm, the acquisition matrix was 256 × 128 × 128, 2 
averages, and echo train length was 8.  An in vivo control eye (no implant) was 
imaged and a representative coronal section was recorded. 
 
 
3.3.3.2 Ex vivo experiments 
NZW rabbits were anesthetized as described above and euthanized  
with an intracardiac pentobarbital overdose (Beuthanasia-D Special, Scheming-
Plough Animal Health Corp., Kemilworth, NJ).  The right eye including the 
conjunctiva, tenon’s fascia, extraocular muscles, and intraconal fat was removed with 
sharp dissection.  The implants were placed on the episclera or vitreous cavity as 
described above.  The eye was immediately wrapped with a 4 in × 4 in gauze pad 
moistened with phosphate buffered saline and placed in a sealed 50 ml conical tube.  
The tube was positioned in a 7.2 cm diameter volume coil and imaged every 10 
minutes for 8 hours.  The parameters were TR/TE = 259/6.6 ms, FOV = 5 cm × 5 cm 
× 4 cm, acquisition matrix size= 256 × 128 × 128, 1 average, and the echo train length 
was 8.  An ex vivo control eye (no implant) was imaged and a representative coronal 






3.3.4 Quantitative analysis of Gd-DTPA from MRI images 
To measure Gd-DTPA concentrations directly from gray scale T1-weighted  
MRI images, standard solutions of Gd-DTPA were scanned along with the rabbit eye.  
The following concentrations of Gd-DTPA were prepared in a 2% hydroxypropyl 
methylcellulose (METHOCEL, Dow Chemical Company, Midland MI) solution: 
1.0×10-1 M, 0.5×10-1 M, 1.0×10-2 M, 0.5×10-2 M, 0.25×10-2 M, 1.0×10-3 M,  
0.5×10-3 M, 1.0×10-4 M, 0.5×10-4 M, 1.0×10-5 M, 0.5×10-5 M, and 1.0×10-6 M.  Each 
of the 12 standard solutions were poured into 12 individual wells cut from a standard 
96 well plate culture chamber and sealed with a silicone adhesive.  Gray scale MRI 
images of the standard solutions were developed and average intensity value of each 




3.4.1 In vitro release rate 
The in vitro release of both the episcleral (n=4) and intravitreal 
 implants (n=4) demonstrated an initial burst with a declining diffusion phase  
(Figure 3-3).  This release pattern is typical of a matrix implant whose release kinetics 




Figure 3-3. Cumulative release (mg ± 1 S.D.) over time of Gd-DTPA from episcleral 
(circle) and intravitreal (square) implants. 
 
 
The episcleral implant released more total drug because of the increased drug  
loading in the manufacturing process.  A total of 4.7 ± 0.49 mg and 3.8 ± 0.14 mg 
were released over 8 hours by the episcleral and intravitreal implants, respectively, 
with 99% of the drug that released occurring by 5 hours in the sink conditions of the 
in vitro assay. 
 
3.4.2 Calibration curve for MRI quantitative analysis 
The relationship of Gd-DTPA concentration and image intensity  
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values were determined during each experiment by scanning the standard Gd-DTPA 
solutions along with the eye.  The lower detection limit of the Gd-DTPA was  
0.5 × 10-5 M and the intensity signal initially increased with concentration up to  
0.5 × 10-2 M (Figure 3-4).  The intensity signal decreased with Gd-DTPA 
concentration beyond 0.5 × 10-2 M because of the T2 shortening effects [80].  
Therefore, area of very high drug concentrations immediately around the implant 
could not be quantified.  Since Gd-DTPA has to be in an aqueous phase to generate a 




Figure 3-4. Calibration curve from standard solutions showing the relationship of Gd-
DTPA concentration and image intensity values in O.D. (optical density) units.  Each 




3.4.3 MRI of in vivo and ex vivo control eyes 
The in vivo MRI image of a control eye had little signal intensity in the  
vitreous and aqueous reflecting good T1 saturation of the tissue water molecules 
(Figure 3-5(A)).  The ex vivo MRI image of a control eye showed a higher signal 
relative to the surrounding tissue (Figure 3-5(B)).  This is due in part to post mortem 
hardening of the tissue and a slightly different TR/TE value for the image.  The 
effective background, however, was within experimental error for detecting Gd-





Figure 3-5. Control eyes (no Gd-DTPA implants); A. in vivo MRI scan (coronal 
image) and B. ex vivo MRI scan (coronal image) 
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3.4.4 Episcleral implant: ocular drug distribution 
In the in vivo experiments with episcleral implants placed at the  
equator of the eye (n=3), Gd-DTPA signal was first observed in the vitreous and 
aqueous humor after a mean of 84.3 ± 12.7 minutes and 115.7 ± 28.4 minutes, 
respectively (Figure 3-6(A) & 3-6(B)).  Over the 8 hour scan, the total mean 
cumulative amount of Gd-DTPA measured in the vitreous and aqueous humor was 
2.7 ± 0.08 µg and 3.1 ± 2.1 µg, respectively.  The mean cumulative amount that 
entered the vitreous and aqueous (i.e. 5.8 µg) was only 0.12% of the total cumulative 
amount released by the implant over an 8-hour period.  No Gd-DTPA signal was 
present in the posterior segment of the eye.  A gradual accumulation of Gd-DTPA 
was noted in the right buccal lymph node in 2 rabbits (Figure 3-7).  In the ex vivo 
experiment with episcleral implants (n=2), one rabbit had an implant placed at the 
equator, the other between the equator and the optic nerve.  The implant placed at the 
equator, Gd-DTPA signal was present in the vitreous within 30 minutes and in the 
anterior chamber within 60 minutes (Figure 3-6(C) & 3-6(D)).  Gd-DTPA was 
present throughout the vitreous cavity and retina with a cumulative amount of 81.3 µg 
in the vitreous, and 67.8 µg in the aqueous humor, after 8 hours of scanning.  In this 
same time frame, the more posterior implant delivered proportionately more Gd-
DTPA into the vitreous (196.6 µg) compared with the aqueous humor (8.7 µg) 










Figure 3-6. MRI scan (coronal images) with an episcleral implant in the right rabbit 
eye. Asterisk shows location of implant.  Bar at the margin correlating Gd-DTPA 
concentration (M) with color in the image. (hr. = hour) 
A. In vivo  image 4 hours post-implant insertion at the equator.  The Gd-DTPA signal 
is predominantly in the subconjunctival space. 
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B. In vivo  image 7 hours post-implant insertion at the equator.  Inset: A Gd-DTPA 
signal is present in the aqueous humor of the posterior chamber (large white arrow) 
and a weaker signal present in the anterior chamber (small white arrows). 
C. Ex vivo image 4 hours post-implant insertion at the equator.  A higher Gd-DTPA 
signal is present throughout the vitreous and aqueous humor compared with the in 
vivo eye in Figure 3-6 A. 
D. Ex vivo image 7 hours post-implant insertion at the equator.  Gd-DTPA is rapidly 
diffusing from the episcleral implant.   
E. Ex vivo image 4 hours post-implant insertion between the equator and the optic 
nerve.   
F. Ex vivo image 7 hours post-implant insertion between the equator and the optic 
nerve.  Because of the posterior location of the implant, a higher Gd-DTPA signal is 
present in the vitreous cavity (and less in the anterior chamber) compared with an 
















Figure 3-7. In vivo MR image of rabbit’s head showing a combined axial and coronal 
image through the right eye.  A reconstructed surface scan of the rabbit’s head (lower 
right inset) shows the image slice orientation.  The episcleral implant (red asterisk) 
right eye shows an adjacent Gd-DTPA signal.  A high signal is present in the right 
buccal lymph node (labeled). 
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3.4.5 Intravitreal implant: ocular drug distribution 
In vivo, Gd-DTPA immediately released into the vitreous and a  
concentration gradient was present in the vitreous cavity with higher levels present 
behind the lens and lower levels at the vitreoretinal interface (Figure 3-8(A) & 3-
8(B)).  There was no difference in the concentration of Gd-DTPA over the medullary 
rays, where retinal vessels are present, compared with the surrounding avacular 
retina.  This Gd-DTPA concentration gradient was absent in the images of the ex vivo 
eyes.  In vivo, there was a slightly higher Gd-DTPA signal at the vitreoretinal 
interface compared with the choroid with minimal signal observed in the sclera 
(Figure 3-9).  In comparison, the ex vivo eyes showed relatively higher concentrations 
of Gd-DTPA at the vitreoretinal interface and low signals in the posterior retina and 
choroid (Figure 3-9).  In vivo, there was a small Gd-DTPA signal present in the 
aqueous humor compared with the large signals in the ex vivo eyes.  In the ex vivo 
eyes, the only clear passage of Gd-DTPA anteriorly appeared through the zonules 
immediately adjacent to the lens into the aqueous humor in the posterior chamber and 











Figure 3-8. MRI scan (coronal images) with an intravitreal implant inserted through 
the equator of the right eye.  Bar at the margin correlating Gd-DTPA concentration 
with color in the image. (hr. = hour) 
A. In vivo image 4 hours post-implant insertion showing movement of Gd-DTPA in 
the vitreous cavity away from the implant. 
B. In vivo image 7 hours post-implant insertion.  The outlined area of the vitreous is 
magnified and shows a sharp decline in Gd-DTPA vitreous concentration (graph) 
from the posterior lens capsule to the retinal surface on the graph. 
C. Ex vivo image 4 hours post-implant insertion showing Gd-DTPA movement into 
the inferior vitreous is more rapid compared with the in vivo images (Figure 3-8 A & 
3-8 B)  
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D. Ex vivo image 7 hours post-implant insertion.  The outlined area of vitreous is 
magnified and shows a shows a small decline in the Gd-DTPA vitreous concentration 







Figure 3-9. Magnified views of the region of the posterior vitreous, retina, choroid, 
and sclera in the outlined areas shown in Figures 3-8 B and 3-8 D.  Above is a 
histologic section of a normal rabbit eye to identify the different ocular tissues in the 




Episcleral implants at the equator of the eye did not deliver a significant 
amount of Gd-DTPA into the vitreous and no Gd-DTPA was present in the posterior 
segment.  An 8-fold increase in vitreous Gd-DTPA concentration occurred in the 
enucleated eyes suggesting that reducing the barriers to drug flux could increase drug 
movement from the episclera into the vitreous.  These barriers include elimination 
pathways such as episcleral and conjunctival venous blood flow [78], conjunctival 
lymphatic drainage [81], choroidal blood flow [82], and counter-directional 
convection currents caused by the difference in hydrostatic pressures between the 
suprachoroidal tissue and the episcleral veins [48, 83].  Our study did not specifically 
identify the principal elimination pathway of Gd-DTPA movement from the 
episclera.  In our study, the presence of a high concentration in the buccal lymph 
node, the proximal portion of the cervical lymph drainage system [84], was consistent 
with previous work showing radiolabeled compounds being eliminated from the 
subconjunctival space [85].  The relatively low flow rates of the lymph fluid in this 
region enables imaging of pooled Gd-DTPA in the lymph node [81].  Entry and 
elimination of Gd-DTPA from the episcleral veins is difficult to image because of the 
rapid dilution of Gd-DTPA as it enters the blood stream.  The entry of Gd-DTPA into 
the aqueous appeared to be predominantly through the ciliary body region.  Drug 
molecules transiting through the ciliary body from the episcleral would less likely be 
eliminated by venous drainage since flow rates are comparatively lower than the 
posterior choroid flow in most species [86], including the rabbit [87].  Other barriers 
to fluid and drug molecule flow from the episclera to the aqueous humor, such as 
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posteriorly directed fluid currents from uveoscleral flow, are negligible in the rabbit 
[88], and lymphatic drainage is absent in the ciliary body and choroid [82].  An 
advocate of fluid and drug molecule movement from the stroma of the ciliary into the 
aqueous humor is the non-pigmented cells of the ciliary epithelium where transport 
occurs through the tight junctions [89], by pinocytosis [90], and via osmotic gradients 
[86].  The passage of Gd-DTPA in the ciliary body region suggests that drugs 
targeting this region, such as aqueous humor production suppressants for glaucoma 
therapy, may be delivered using episcleral implants. 
Implants placed directly in the vitreous cavity at the equator in live rabbits  
released Gd-DTPA produced a concentration gradient in the vitreous, lowest near the 
vitreoretinal interface.  Based on previous experiments where fluorescein compounds 
were injected in the vitreous and sections of frozen eyes were examined, a gradual 
reduction in the vitreous concentration contours of sodium fluorescein from anterior 
to posterior was suggestive of a transretinal elimination pathway [62, 75].  The Gd-
DTPA concentration gradient in the vitreous was abolished when the implants were 
imaged in the vitreous of enucleated eyes and the concentration was markedly 
reduced at the level of the RPE and the choroid.  This suggested that the major 
transport mechanisms are inactivated when the eye was enucleated.  Mechanisms that 
encourage transretinal fluid and drug molecule movement include higher hydrostatic 
pressures in the anterior vitreous compared with the episcleral space [91], oncotic 
pressure gradients created by the proteinaceous extracellular fluid of the choroid [86, 
92], and rapid clearance via the choroidal blood flow [93].  The movement of Gd-
DTPA released from an intravitreal implant through the neurosensory retina was 
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observed in both in vivo and ex vivo eyes, consistent with the lack of tight junctional 
barriers in the neurosensory retina [94].  Although choroidal tissue fluid can leave the 
eye via the sclera, either in or around perivascular spaces [85, 88, 95], in the in vivo 
intravitreal implant eyes, no Gd-DTPA was appreciated in the posterior sclera 
suggesting the elimination of Gd-DTPA was predominantly via the choroidal 
circulation.   
In vivo, comparing the transport of Gd-DTPA released from an intravitreal  
implant in the vitreous by flow-induced convection, with that of diffusion, can be 
characterized with the Péclet number (Pé): 
Pé= V·L/ D 
where 
V   velocity of water in vitreous:  3.3 × 10-7 cm/sec [62] 
L   radius of the retina of rabbit:  1 cm [6] 
D  diffusion coefficient of Gd-DTPA in water:  3.8 × 10-6 cm2/sec [96] 
Pé = 0.087 
 
This Péclet number suggests that the movement of Gd-DTPA in the vitreous  
was predominantly by diffusion, consistent with other studies examining the 
movement of small molecular weight compounds in the vitreous [83]. 
There was more rapid movement of Gd-DTPA in the aqueous and vitreous 
humor in the ex-vivo eyes with an intravitreal implant compared with the in vivo eyes 
because of the lack of transretinal clearance from the vitreous and loss of aqueous 
humor drainage.  The ex vivo eyes showed a relative obstruction of Gd-DTPA 
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diffusion from the vitreous cavity to the posterior chamber, likely due to the dense 
vitreous condensation in this region [97, 98].  The pooling of Gd-DTPA in the 
posterior chamber of these eyes was due to the strong iris / lens apposition in rabbits 
where the iris acts like a one-way valve permitting anterior flow only [99].   
There are a number of differences in the anatomy and physiology of the rabbit 
eye that have to be considered before extrapolating the results of this chapter to 
humans [78].  Although the permeability of rabbit and human sclera to a number of 
compounds is similar [25], the mean scleral thickness is less in the rabbit [78] 
compared with the human and this can have an effect on trans-scleral drug transport 
[100].  The choroidal vessel permeability and flow is different in rabbits compared 
with primates [82, 101, 102].  For example, the choroidal flow is 16% higher in 
rabbits compared with monkeys [103, 104] which may increase elimination of drug 
transiting to the vitreous released from an episcleral implant.  Although there are 
minor variations in choroidal blood flow within the same eye of the rabbit, major 
variations occur in primates where flow in the macula is a log unit higher than in the 
retinal periphery [105], and this may have an impact on the transit of drug molecules 
into the eye from an episcleral implant.  Another important difference between rabbits 
and humans is the degree of retinal vascularization; the rabbit possessing a 
merangiotic retina (i.e. partially vascularized retina) and the human a holangiotic 
retina (i.e. completely vascularized retina).  In rabbit, the MRI images in the region of 
the retinal vessels of the medullary rays showed no difference in signal compared 
with other areas of avascular retina.  Since retinal blood flow is a fraction of choroidal 
blood flow [106], the amount of Gd-DTPA being eliminated via the retinal circulation 
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may not be significant or it may be below the resolution of this MRI technique.  
Clearance of drugs via the retinal circulation may be more a factor in humans where 
the retinal vascularization is complete. 
There are limitations in the interpretation of the data in this study.  Gd-DTPA 
concentrations could only be quantified between 0.5 × 10-5 M and 0.5 × 10-2 M which 
did not allow for quantification of the high Gd-DTPA concentrations around the 
implant.  Furthermore, with the resolution of the MRI system being in the micromolar 
range, Gd-DTPA in lower concentrations would not have been identified in the ocular 
tissues.  The post-mortem effect of the ocular tissues on drug movement was not 
specifically examined in this study.  However, in vitro studies of accessing ocular 
tissue drug transport suggest that isolated sclera from rabbits and humans and flat 
mount preparations of the retinal pigment epithelium and choroid [107] can remain 
structurally [100] and functionally [25] viable for a number of hours.  Although the 
blood flow is terminated once an eye is enucleated, endothelial cell tight junctions can 
remain functionally intact for several hours following an ischemic insult to the 
endothelial cells in vitro [108].  In addition, the fact that Gd-DTPA movement 
through the retina was significantly delayed with an accumulation of Gd-DTPA in the 
vitreous of the enucleated eyes with the intravitreal implants suggests that the outer 
blood-retinal barrier, i.e. the tight junctions between RPE cells, remained intact.  
Another limitation of this study is we examined the movement of a single drug 
surrogate, at one concentration, from the implants.  Since the molecular weight, 
hydrodynamic radius, and the solubility of a compound in water influences the ocular 
penetration of a compound [25, 100], Gd-DTPA, a low molecular weight and 
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hydrophilic compound, does not have general applicability to the movement and 
transport of all drugs in the eye.  However, improvements in drug labeling techniques 
with metal ion chelates with a variety of therapeutic compounds have begun to 
revolutionize assessments of drug distribution throughout the body using MRI [109, 
110] and applying these new technologies will improve the general understanding of 
drug movement in the eye as a function of molecular weight, hydrodynamic radius, 
and solubility.  
 
3.6 Conclusions 
Episcleral implants at the equator of the eye did not deliver a significant 
amount of Gd-DTPA into the vitreous and no compound was present in the posterior 
segment.  An 8-fold increase in vitreous Gd-DTPA concentration occurred in the 
enucleated eyes suggesting that there are significant barriers to the movement of 
drugs from the episcleral space into the vitreous in vivo.  Dynamic MRI using Gd-
DTPA, and potentially metal ion/drug complexes, may be useful in understanding the 









CHAPTER 4. Transport of drugs released from an intravitreal 
implant by comparing magnetic resonance imaging data to a 
finite element mathematical model 
 
4.1 Objectives 
Several parameter values will be calculated by comparing simulation data to  
experimental data and the concentration distribution of model drugs released from an 
intravitreal implant at several cases will be estimated with the developed 
mathematical eye model. 
 
4.2 Introduction 
MRI has been utilized to investigate the anatomy and pathology of the eye  
non-invasively [31, 35, 37, 111].  We employ MRI to overcome limitations in 
autoradiography and fluorescence, which do not yield real-time information and 
require tedious dissection procedures, and to determine non-invasively the real-time 
movement of a drug surrogate, gadolinium-diethylenetriaminopentaacetic acid (Gd-
DTPA) released from a polymer-based intravitreal implant.   
In this chapter, we developed a finite element mathematical eye model to help  
analyzing MRI experiment data and calculated several physiological parameters by 
comparing simulation data to MRI experimental data.  With the developed 




4.3 Materials and methods 
4.3.1 Intravitreal implant design 
An intravitreal implant was manufactured using the procedure as  
shown in Figure 3-2: 15% polyvinyl alcohol (PVA) (w/v) solution was formulated by 
placing 1.5 g of PVA (Celvol, Celanese Chemicals, Ltd., Dallas, TX) in 10 ml of 
molecular biology grade water (BIOfluids®, Biosource International, Camarillo, CA) 
in a 50 ml polypropylene conical tube (Falcon®, BD Biosciences, Franklin Lakes, NJ) 
and placed in a water bath at 100°C for 3 hours to dissolve all the PVA.  The PVA 
solution was cooled down to room temperature and 0.80 ml of 0.5 M Gd-DTPA 
solution was added and stirred into the PVA mixture to produce a solution of 15% 
PVA and 20% Gd-DTPA (w/w/v).  Eight ml was poured onto a glass plate which 
produced a thin film as it dried at room temperature.  A biopsy punch (Acu·Punch® 3 
mm, Acuderm Inc, Ft. Lauderdale, FL) was used on the dried film to make 3 mm 
diameter disks.  Individual disks (7 total) were placed in a polytetrafluorethylene 
mold, which has a 3.2 mm diameter and a 1.2 mm depth.  The disks were coated with 
the remaining 15% PVA and 20% Gd-DTPA (w/w/v) solution.  The dried implant 
was peeled out of the polytetrafluoroethylene mold and a total of 3.7 mg of Gd-DTPA 
was loaded into each intravitreal implant. 
 
4.3.2 In vitro release rate 
In vitro release rate experiments were performed on the fabricated  
implants over an 8 hour period, which was equivalent to the MRI experiment time 
period.  Implants were placed in 25 ml glass vials with 20 ml of phosphate buffered 
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saline (PBS) (pH 7.4) and stirred at 150 rpm at room temperature.  The solution was 
assayed ever 10 minutes for the first hour, every 30 minutes for the second hour, and 
then hourly up to 8 hours.  The PBS solution was completely replaced with fresh PBS 
at each sample time to simulate sink condition.  Gd-DTPA assays were performed 
using a spectrofluorometer (QuantaMaster, Photon Technology Internation, 
Lawrenceville, NJ) at excitation wavelength 275 nm; emission wavelength 312 nm.  
The release rates were determined by calculating the amount of Gd-DTPA released 
over time and recorded as mg per hour. 
 
4.3.3 Magnetic resonance imaging  
4.3.3.1 Standard solutions for quantitative analysis of MRI images 
To compare successive MRI images from day to day and to  
calibrate the amount of Gd-DTPA in the vitreous and in the aqueous humor, standard 
solution of known Gd-DTPA concentration were always scanned along side the rabbit 
eyes.  The standard solutions were prepared by adding varying amounts of 0.5 M Gd-
DTPA solution to 2 % hydropropyl methylcellulose (HPMC) (METHOCELL®, Dow 
Chemical) solution to make 1.0×10-1M, 0.5×10-1M, 1.0×10-2M, 0.5×10-2M,  
0.25×10-2M, 1.0×10-3M, 0.5×10-3M, 1.0×10-4M, 0.5×10-4M, 1.0×10-5M, 0.5×10-5M, 
and 1.0×10-61M calibration solutions.  Each of the 12 calibration solutions was sealed 
with silicone into 12 individual wells cut from a standard 96 well plate culture 
chamber (VWR international, Bridgeport, NJ, USA).  Gray scale images of the 
standard solutions were developed and the average intensity value of each 
concentration was determined using imageJ software (version 1.27z, National 
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Institutes of Health, Bethesda, USA).  A concentration curve of image intensity 
versus Gd-DTPA concentration was generated. 
4.3.3.2 In vivo experiment 
All imaging experiments were performed ex vivo and in vivo  
on New Zealand White rabbits in a 4.7 Tesla magnet equipped with a Bruker Avance 
console (Bruker-biospin, Billerica, MA).  The procedures adhered to the guidelines 
from the Associated for Research in Vision and Ophthalmology for animal use in 
research.  All analyses and manipulations of images were performed using MATLAB 
(version 6.5, Mathworks Inc., Natick, MA, USA) and AMIRA (version 2.3, TGS Inc., 
San Diego, CA, USA).  Each rabbit was maintained under general anesthesia during 
the entire imaging period.  The animals were induced with xylazine (5–10 mg/kg) and 
ketamine (35-50 mg/kg IM to effect) and an IV catheter was inserted into the 
marginal ear vein to administer fluids.  An endotracheal tube was placed and 
anesthesia was maintained with 1-2% halothane or 1-2% isoflurane.  The conjunctiva 
was opened with a stab incision (using a Beaver blade), and an intravitreal implant 
was placed into the vitreous chamber.  The implant was sutured to the sclera; the 
sclera and conjunctiva were closed with suture.  After completing this preparation, the 
rabbit was positioned in the MRI.  T1-weighted MRI studies were performed using a 
10 cm diameter volume coil and a Fast Spin Echo sequence.  MRI scanning 
parameters were repetition time (TR)/echo time (TE) = 200/9.0 ms, with a 9 cm × 9 
cm × 9 cm field of view (FOV), and a 256 × 128 × 128 acquisition matrix size for the 
in vivo experiment.  A complete 3D data set was acquired every 20 minutes.  During 
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the study, pulse, blood oxygenation (SpO2), end-tidal CO2, respiratory rate, anesthetic 
gas levels, and body temperature were monitored.  
4.3.3.2 Ex vivo experiment 
Eyes were enucleated from euthanasized rabbits.  The  
conjunctiva was opened approximately 2 mm posterior from the limbus.  The exposed 
sclera was opened with a stab incision (using a Beaver blade), and an intravitreal 
implant was placed into the vitreous chamber.  The implant was sutured to the sclera; 
the sclera and conjunctiva were closed with suture.  After placing the implant in the 
vitreous, the eye was placed in a 50 ml centrifugal tube, on a wet (sterile saline) 
sterile 4 inch × 4 inch gauze pad, to keep the eye moisturized.  After completing this 
preparation, the tube was immediately positioned in the MRI.  The eye was scanned 
every 10 minutes for 20 hours using a 72 mm diameter volume coil and a Fast Spin 
Echo sequence.  MRI scanning parameters were TR/TE = 200/6.6 ms, FOV = 5 cm × 
5 cm × 4 cm, echo train length = 8 ms, 256 × 128 × 128 acquisition matrix size, and 2 
averages. 
 
4.3.4 3-D computer simulation 
A 3-D finite element mathematical model of the eye was developed  
using FEMLAB software (version 2.3, Consol Inc., Burlington, MA, USA) to help 
analyze MRI images and understand the transport of Gd-DTPA released from an 
intravitreal implant.  The geometry of the mathematical model of the eye was based 
on the physiological dimensions of a rabbit eye [6] and was composed of the vitreous, 
the lens, the posterior surface of the eye, and the implant (Figure 4-1(A)).  In this 
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initial model, the posterior surface is described as a “lumped” region consisting of a 
combination of the sclera-choroid-retinal barrier.  A total of 21174 finite element 











FIGURE 4-1. (A) Geometry of mathematical eye model. (a): intravitreal implant; (b): 





To determine the velocity distribution of the fluid movement through the eye,  
Darcy’s law was applied to the vitreous compartment and to the sclera-choroid-retinal 
membrane [91]: 
                                          pK ∇−=
→
µ
U                                                            (1) 
where, U  is the velocity of the fluid, K is the hydraulic conductivity of the vitreous 
or sclera-choroid-retinal membrane, µ is the viscosity of the fluid, and  is the 
pressure gradient.  Values of the hydraulic conductivity for vitreous gel and the 
sclera-choroid-retinal membrane and for the viscosity of the aqueous fluid were 
derived from the literature (see Table 4-1).  Pressures of 15 mmHg and 10 mmHg 
were applied to the hyloid and the outer sclera, respectively, to achieve a 5 mmHg 
pressure drop between these elements [112].  The lens and the implant were 
considered to be impermeable to fluid flow; so, a zero velocity fluid flow boundary 
condition was applied throughout the lens and the implant.  To calculate the 
concentration distribution of the released Gd-DTPA in the vitreous region and the 
sclera-choroid-retinal membrane, the following diffusion-convection equation was 
solved [48]:  
→
p∇




                                      (2) 
where, ρ is the density of fluid, D is the diffusion coefficient of Gd-DTPA in the 
vitreous, U  is the velocity of fluid in the vitreous, and C is the concentration of Gd-
DTPA.  To expedite computation, the steady state vitreous velocity distribution of the 




exported into and superimposed on the diffusion-convection equation to determine 
concentration distribution of Gd-DTPA in the vitreous.   
 
Table 4-1. Parameter values used in the simulation study. 
 
Parameter Value Reference 
Density of aqueous humor 1 g cm-3 Friedrich et al., 1997 
Viscosity of aqueous humor 6.9×10-3 g cm-1 sec-1 Friedrich et al., 1997 
Pressure at the hyaloid 15 mmHg Missel, 2002 
Pressure at the episclera 10 mmHg Missel, 2002 
Hydraulic conductivity in the 
sclera 1.5×10
-11 cm2 Pa-1 sec-1 Xu et al., 2002 
Hydraulic conductivity in the 
vitreous 2.4×10
-6 cm2 Pa-1 sec-1 Xu et al., 2002 
Diffusivity of Gd-DTPA in 
the vitreous ? Estimated from this study 
Permeability of Gd-DTPA in 
the sclera ? Estimated from this study 
 
 
A mass flux boundary condition was imposed on the surface of implant to simulate 
the in vitro release (Figure 4-2).  At the outer boundary of the sclera-choroid-retinal 
region (episclera), a zero concentration boundary condition was applied.  This would 
represent a rapid “sink” condition, possibly resulting from rapid clearance by 
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choroidal blood flow.  A continuity condition was applied at the interface between the 
vitreous and sclera-choroid-retinal membrane region of the eye both in the flow 
velocity calculation and in the diffusion convection calculation.  The current model 
does not include an anterior segment.  In order to account for the loss of drug to the 
anterior segment, a boundary condition was used at the hyloid membrane that 
represented drug clearance to the anterior region.  The clearance was represented in 
the model as flux boundary condition of the drug concentration at the hyloid 
membrane times the aqueous humor turnover rate divided by the hyloid area [48]: 
Flux of drug clearance = - ( f / A) × C 
where, A is the hyaloid area, f is the turnover rate of aqueous humor, and C is the 
concentration at the hyloid membrane.  The Gd-DTPA clearance value equaled 
6.16×10-5 [cm/ sec] × C.  Other parameter values that were used for the mathematical 
eye model are listed in Table 4-1.  Model simulations were compared to MRI 
concentration data on a relative quantitative basis.  The following procedure was 
followed.  Individual X-Y voxel positions were averaged over ten adjacent Z-plane 
MRI image slices, each 350 micron thick, near the center axis of the eye to obtain an 
X-Y planar concentration profile for Gd-DTPA averaged over a 3.5 mm Z thickness.  
The averaging smoothed out slight image irregularities in any given 350 micron 
image slice and provided a concentration profile from the lens to the retina the X-Y 
plane to compare to the simulation concentrations in a similar plane.  Concentration 
values were normalized relative to that at the lens surface to account for variations in 
the implant release rates [4].  Relative concentration profiles from lens surface to 
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FIGURE 4-2. (A) Release rate of Gd-DTPA from intravitreal implants; (B) 





4.4.1 MR images: 
(A) In vivo 
Figure 4-3 shows the MRI intensity images in a rabbit eye at 1.5, 2.7,  
4.1, and 7.7 hour following insertion of an intervitreal Gd-DTPA matrix implant.  The 
dark rectangle outlines the implant location and appears black due to the saturation T2 
effects of the high Gd-DTPA concentration in the implant.  The large oval-shaped 
dark region to the lower right of the implant is the rabbit lens which is impermeable 
to Gd-DTPA and appears black due to insignificant concentration.  Gd-DTPA can be 
seen to disperse through large regions of the vitreous compartment as time 
progresses.  There is a definite concentration gradient as one recedes away from the 
implant.  A distinct concentration gradient is maintained with the in vivo system for 
up to nearly 8 hour post-implantation.  Some Gd-DTPA was evident at the incision 
site which may have occurred by the implant contacting moist tissue during insertion 
or by some leakage or diffusion of Gd-DTPA back to the incision area.  Very little 
signal intensity is seen in the anterior chamber of the in vivo eye in Figure 4-3.  Also, 
a dark ring is observed around the posterior segments of the eye in an area of the 





















































Standard                          (A)                                                                   (B) 
                         (C)                                                                     (D) 
IGURE 4-3. In vivo intravitreal implant MR images. (A) 1.5 hour post implantation, 
B) 2.7 hour post implantation, (C) 4.1 hour post implantation, and (D) 7.7 hour post 
mplantation.  
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(A) Ex vivo 
Figure 4-4 shows the MRI images in an ex vivo rabbit eye at 1.2, 2.6,  
4.6, and 10.1 hour post implantation.  These images show more spatial resolution near 
the eye since a surface coil was placed closer to the eye during these ex vivo 
experiment.  The PVA implant is clearly visible as the thin rectangular dark region.  
The large rabbit lens is impermeable to Gd-DTPA and remains dark.  The Gd-DTPA 
is seen to diffuse in both anterior (toward the aqueous chamber) and posterior (toward 
the retina) direction.  Since there is no clearance by aqueous outflow in the ex vivo 
eye, Gd-DTPA begins to diffuse through the hyloid membrane.  In contrast to the in 
vivo case, Gd-DTPA can accumulate in the aqueous compartment.  At 10.1 hour, the 
image intensity within the implant actually appears to brighten since the implant’s 
Gd-DTPA concentration is diminishing below the saturation values (black image).  
The image intensity at 10.1 hours shows a substantially more uniform concentration 
distribution from the back of the lens toward the retina with essentially no gradient as 
one proceeds distal to the implant.  This ex vivo distribution represents a distinct 
contrast to the in vivo data and most likely occurs due to the lack of transport of Gd-
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vitreal implant MR images. (A) 1.2 hour post implantation, 
tion, (C) 4.6 hour post implantation, and (D) 10.1 hour post 
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Figure 4-5 and 4-6 show the in vivo and ex vivo profiles of Gd-DTPA  
concentration calculated from the intensity images along a line drawn from the lens to 
the retina.  For the in vivo case, the concentration profile for Gd-DTPA from the lens 
to the retina appears to approach a quasi steady state by 7.32 hour post implantation 
and there is a persistent concentration gradient at the retina surface.  For the ex vivo 
experiment, the concentration profile becomes relatively flat by 6.68 hour and 
subsequently remains without a gradient. 
Figures 4-7 and 4-8 show the in vivo and ex vivo MRI experimental Gd-DTPA  
concentration profiles taken along the vertical line from the middle of the vitreous to 
side opposite to the implant.  In Figure 4-7, there is still a significant drop in Gd-
DTPA concentration from the implant side of the vitreous compartment (x-axis 0 cm) 
to the far (x-axis 1.0 cm) side at the longest experimental time point of 7.7 hour.  A 
similar situation exists for the ex vivo case, as shown in Figure 4-8, except that by 



















FIGURE 4-5. Concentration distribution of Gd-DTPA from the lens to the retina in in 















FIGURE 4-6. Concentration distribution of Gd-DTPA from the lens to the retina in ex 




























FIGURE 4-7. Concentration distribution of Gd-DTPA from the middle of the vitreous 


























FIGURE 4-8. Concentration distribution of Gd-DTPA from the middle of the vitreous 













4.4.2 3-D computer simulation 
From the mathematical eye model, the velocity distribution of the fluid 
 convection in the vitreous compartment was calculated.  Figure 4-9 shows a steady 
state, gray scale velocity contour with arrows marking velocity directions.  The fluid 
flows from the hyloid membrane toward and then out through the retina-choroid-
sclera membrane.  The average velocity through the retina-choroid-sclera surface is 
reported by Missel [48] to be approximately 3.52 × 10-7 cm/sec and that near the 
optical nerve is reported by Araie [62] to be 3.9 × 10-7 cm/sec.  This version of the 
model does not include explicitly flow from the ciliary body toward the anterior 
compartment.  The movement of Gd-DTPA to the anterior compartment was 
described with a clearance term consisting of aqueous humor turnover divided by 
hyloid area in the Methods section.  
The vitreous diffusion coefficient and retina-choroid-sclera barrier  
permeability was determined by a trial and error process that optimized agreement 
between the MRI data and the simulation.  In this process, the diffusivity value of Gd-
DTPA in vitreous was initially set at 3.8 × 10-6 cm2/sec according to Gordon et al. 
[96].  Then, by a series of trial simulations, we obtained a model of diffusion 
coefficient through the 0.03 cm thick retina-choroid-sclera membrane for the  
3.0 × 10-7 cm2/sec.  This translates to an equivalent permeability of 1.0 × 10-5 cm/sec.  
Subsequently, the vitreous diffusion coefficient was readjusted to a value of  
2.8 × 10-6 cm2/sec to improve the final fit between simulation and MRI concentration 
data.  The fitting was optimized by visual inspection of Figure 4-10. 
Figure 4-11 shows surface plots from model simulation of the concentration  
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distribution of Gd-DTPA in the vitreous at several time points.  Qualitatively, the 
model shows a time course and a pattern of drug dispersion similar to those suggested 
in in vivo images.  Few representative concentration profiles determined by the 
simulation are plotted in Figures 4-12 and 4-13.  These profiles, along a horizontal 
axis from the back of the lens to the retina, also shows similar qualitative behaviors to 
the MRI data in Figures 5 and 6 for the in vivo and ex vivo cases.  In Figure 4-12, the 
concentration increases at the lens surface (x = 0 cm) with time and subsequently 
decreases as the release rate from the implant diminishes.  At the retina surface (x = 
0.65 cm), a concentration gradient is always evident.  In Figure 4-13, where the 
permeability is set to zero to simulate the ex vivo case, the concentration profile 
approaches uniformity over time from the lens to the retina and then reaches the 
steady state distribution.   
From instructional purposes, some concentration profiles under hypothetical  
steady state conditions were determined with the finite element model.  The actual 
experimental Gd-DTPA release rate was time varying and steady state could not be 
achieved.  For steady state simulations, a constant release rate of 0.1 mg/hour was 
used.  This release rate represents a nominal average value of hypothetical in vivo and 
ex vivo experiments with the implant.  Figures 4-14 A through D show hypothetical 
concentration profiles along an axis from the back of the lens to the retina at different 
times as predicted by the model for four different values of the retina-choroid-sclera 
permeability coefficients, 1.0 × 10-4 cm/sec, 1.0 × 10-5 cm/sec (the predicted in vivo 
value), 1.0 × 10-6 cm/sec, and zero (the assumed ex vivo value).  At a low 
permeability, 1.0 × 10-6 cm2/sec and especially at zero permeability, the concentration 
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gradient at the retina surface almost vanished.  The longest time point for a profile 
shown in Figure 4-14 is 20 hour, which appears to represent steady state since there is 
no little further change in the profile with time in the case of retina-choroid-sclera 
permeability coefficient of 1.0 × 10-4 cm/sec.   
A theoretical representation by computer simulation of concentration profiles 
along a vertical axis (Figure 4-7 and 4-8) from the implant to the opposite side of the 
vitreous compartment is shown in Figure 4-15 for a condition representing the in vivo 
case (permeability = 1 × 10-5 cm2/sec) and in Figure 4-16 for the ex vivo case 
(permeability = zero).  Even as steady state appears to be achieved by 20 hour in the 
simulations in the in vivo case, concentrations opposing the implant continue rising 





























FIGURE 4-9. Mathematical study results: The steady-state velocity distribution of 
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7.7 hours 3.8 hours
5.9 hours 7.7 hours
 
 
FIGURE 4-10. Comparison between in vivo MRI experiment and simulation with 3.0 
× 10-7 cm2/sec for diffusion coefficient in the posterior segment of the eye and  
2.8 × 10-6 cm2/sec in the vitreous. Concentration from the lens to the retina was 

















FIGURE 4-11. Mathematical study results: (1), (2), (3), and (4) show concentration 
distribution at 1.50 hour, 2.68 hour, 4.12 hour, and 7.67 hour post implantation. Unit 







































FIGURE 4-12. Simulated concentration distribution profiles from the back of the lens 










































FIGURE 4-13. Simulated concentration distribution profiles from the back of the lens 

























FIGURE 4-14. Simulated concentration profiles with time along an axis from the 
back of the lens to the retina simulated for four different values of the R-C-S 
permeability coefficients; (A) 1.0 × 10-4 cm/sec, (B) 1.0 × 10-5 cm/sec, (C) 1.0 × 10-6 



























FIGURE 4-15. Simulated concentration profiles with time along an axis from the 













FIGURE 4-16. Simulated concentration profiles with time along an axis from the 
implant to the other side of the vitreous for ex vivo case with a release rate of 0.1 










 Information on the movement of drugs in the eye is important in  
determining efficient drug delivery routes, developing new drug delivery methods, 
and delivering drugs within the desired concentration ranges to the target site with 
minimal side effects.  In this study, we investigated the movement of a small 
hydrophilic drug surrogate, Gd-DTPA (molecular weight = 958), released from an 
implant that was placed in the vitreous cavity of White New Zealand rabbits in both 
in vivo and ex vivo experiments.  The transport of the Gd-DTPA was monitored by 
MRI and quantification of Gd-DTPA concentrations over time was obtained.  The 
Gd-DTPA vitreous concentration profiles in rabbit eyes were correlated with a finite 
element mathematical model of the rabbit eye.  Results of the mathematical analyses 
were the estimation of transport parameters in the rabbit eye such as vitreous 
diffusion coefficients and retinal-choroidal-scleral permeability (Table 4-2).   
  
Table 4-2. Results of mathematical analyses. 
 
A finite element mathematical model 
• diffusion coefficient of Gd-DTPA in the vitreous: 2.8 × 10-6 cm2/sec 





MRI has proven to be a very useful tool for analyzing drug delivery in  
the eye.  The technique is non-invasive and gives results in 3-D and in real time.  
Lizak et al. [113] used a modified fast spin echo sequence technique to image human 
lenses and was able to detect differences between normal and cataractous eyes.  
Previous studies reported the use of T1- weighted MRI imaging for analyzing the 
diffusion of Gd-DTPA through PVA hydrogels [96] and for measuring bioreactor 
perfusion [114].  These studies analyzed MRI experimental data quantitatively with 
the relationship between T1 relaxed values and concentration using inversion recovery 
MR imaging technique.  Kolodny et al. [111, 114, 115] used MRI to study the eye.  
They concluded that plasma-derived proteins bypass the posterior chamber of the eye 
and enter the anterior chamber directly via the iris root.  Their analysis was based on 
MRI images following intravenously injected Gd-DTPA rather than specific proteins.  
Several studies used contrast enhanced MRI to investigate the breakdown of the 
blood-retinal barrier created by chemical induction or by photocoagulation.[37, 116, 
117]  Berkowitz et al. (1991) produced panretinal photocoagulation in pigmented 
rabbits and reported a “leakiness” parameter to describe the increase in the 
permeability of the retina by comparing the brightness of Gd-DTPA images from the 
vitreous [116].  Berkowitz et al. (1992) and Sen et al. (1992) used contrast enhanced 
MRI to study the chemical-induced breakdown of two separate components of the 
blood-retinal-barrier: the outer barrier composed of the retinal pigment epithelial cells 
(RPE) and the inner barrier consisting of the retinal vascular endothelial cells.  From 
their results, they calculated a “modified” permeability-area parameter and they 
concluded that the RPE disruption resulted in a greater increase in retinal 
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permeability than vascular disruption.  They also reported a retinal permeability-area 
product parameter for control rabbits of 8.8 × 10-6 cm/sec [117], which compares 
quite favorably with our estimate of the retina-choroid-sclera layer Gd-DTPA 
permeability parameter of 1.0 × 10-5 cm/sec which was used in our finite element 
model.  This model retina-choroid-sclera permeability is equivalent to a diffusion 
coefficient of 3.0 × 10-7 cm2/sec through a retina-choroid-sclera layer of 0.03 cm 
thickness.  
Our best fit model diffusion coefficient value for Gd-DTPA in the vitreous 
compartment was 2.8 × 10-6 cm2/sec.  This value compares to a free aqueous diffusion 
coefficient of 3.8 × 10-6 cm2/sec as calculated by the Stokes-Einstein equation for a 
sphere [96] and 2.7 × 10-6 cm2/sec calculated by the Wilke-Chang empirical theory 
using a specific volume of 0.77 ml/gm [118].  The vitreous is a porous medium 
composed of approximately 99% (w/w) water and 1% collagen fibers [119].  The 
close agreement of the model vitreous diffusion coefficient with those estimated from 
free diffusion theory would suggest that the collagen matrix provides minimal 
hindrance to diffusion of the relatively low molecular weight Gd-DTPA.   Missel [48] 
assumed a diffusion coefficient for the retina-choroid-sclera region in his 
mathematical model that was one sixth of the vitreous diffusion coefficient.  
Applying this one sixth scaling factor to our model vitreous diffusion coefficient of 
2.8 × 10-6 cm2/sec results in an estimate of an retina-choroid-sclera diffusion 
coefficient of 4.7 × 10-7 cm2/sec which compares to the 3.0 × 10-7 cm2/sec derived 
from our finite element model.   
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The previous reports in the literature of image enhanced MRI studies of the 
eye were done with intravenous injections of Gd-DTPA.  To our knowledge, our 
study is the first quantitative report of transport in the eye for compounds delivered 
by intravitreal implants.  The concurrence of our permeability parameter derived from 
intravitreal delivery with that of Sen et al. [117] following intravenous injections 
would imply asymmetrical trans-retinal transport for Gd-DTPA.  This result supports 
the assertion of Berkowitz [116] that transport of Gd-DTPA is by passive diffusion 
and not active transport.   
 Other mathematical simulations of drug delivery to the eye have been 
published.  Ohtori and Tojo [120] reported a computer simulation of drug delivery to 
the eye from intravitreal injections using dexamethasone sodium m-sulfobenzoate 
(DMSB) as the model drug.  They concluded that the major route of elimination was 
via the posterior aqueous humor, especially for hydrophilic drugs, but that the retina-
choroid-sclera membrane, because of its large area, cannot be overlooked, especially 
for lipophilic drugs.  Tojo and Isowaki [44] presented a pharmacokinetic model for 
intravitreal drug delivery based on an analysis of diffusion in a cylindrical vitreous 
body model.  They modeled source terms for drug delivery that mimicked reservoir-
type and matrix-type release of gancyclovir and the release of DMSB from 
biodegradable polymer rods.  They showed good agreement between average vitreous 
concentration data and model simulations, but their study did not include spatial 
determination of drug concentration.  Freidrich et al. [4] presented a sophisticated 
finite element model of the rabbit eye.  Their analysis included fluorescein transport, 
which is highly permeable through the retina, and fluorescein glucuronide transport, 
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which poorly permeates the retina.  Examination of the fluorescien simulations shows 
significant concentration gradients normal to the retinal surface, but for fluorescien 
glucoronide, these gradients are absent and shows instead concentration contours 
lines that are perpendicular to the retina.  Their simulations are in agreement with the 
data of Aureie and Maurice [62] and reflect the findings or our Gd-DTPA MRI data 
and simulations for the in vivo and ex vivo experiments.  That is to say, in our in vivo 
experiment, Gd-DTPA is apparently permeable through the retina-choroid-sclera 
layer and shows a sustained concentration gradient at the retinal surface.  In our ex 
vivo experiments, there is no permeation of the Gd-DTPA through the retina-choroid-
sclera layer, and this results in the absence of a concentration gradient at the retinal 
surface. 
 None of the previous models discussed above include convective flow through 
the vitreous compartment.  The relative importance of convective fluid flow in vitreal 
drug movement is an unsettled issue in drug transport studies in the eye.  Our model 
includes convection velocities in the vitreous which were calculated from normal 
intracoular pressures at the hyloid membrane (15 mm Hg).  The fluid velocities vary 
somewhat as one traverses from the hyloid membrane toward the posterior segments 
of the vitreous near the retina since there is an expanding cross sectional area for 
flow.  A nominal velocity for flow through the retina-choroid-sclera barrier in our 
model is 3.5 × 10-7 cm/sec.  This compares favorably with a value of 3.9 × 10-7 
cm/sec reported by Araie and Maurice [62] and 3.5 × 10–7 cm/sec reported by Missel 
[48].  Missel concludes that hydraulic flow is not likely to be of clinical significance 
for movement of low molecular weight drugs, especially if they are efficiently cleared 
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in the choroid.  Likewise, our computer simulations show that reducing the 
convective flow to zero in the model produces essentially no change in the Gd-DTPA 
concentration profiles within the vitreous, suggesting that diffusion is the dominant 
mechanism for transport in our system.  Xu et al. [91] calculated numbers to be 0.4 
for a human eye and 0.024 for a mouse eye.  The Péclet number reflects the relative 
importance of flow versus diffusion in transport.  Using a nominal velocity at the 
retinal surface of 3.5 × 10-7 cm/sec, a diffusion coefficient of 3.8 × 10-6 cm2/sec in the 
vitreous, and a nominal length scale of 1.0 cm for the diameter of the vitreous cavity 
of a rabbit eye, we calculate a Péclet number (vL/D) of approximately 0.09 which 
implies a dominance of diffusion over flow in affecting the concentration distribution 
of the Gd-DTPA in the vitreous.  Xu’s velocity estimate for the Péclet number was 
based on a Darcy’s Law calculation using the combined resistance to flow calculated 
from the vitreous and scleral hydraulic conductivities, but any contribution to flow 
resistance from the retinal layer was ignored.  They obtained a velocity value of  
1.0 × 10-6 cm/sec which is about three times higher than our model value and the 
values reported by Missel [48]. 
 The implant was placed in one side of the vitreous near the hyloid membrane,  
not in the middle of the vitreous because of surgerical difficulty, and the intensity 
gradient of Gd-DTPA across the vitreous from the middle of the vitreous to the other 
side of the vitreous was shown in the MRI images (see Figures 4-7 and 4-8).  The 
previous simulation study showed asymmetric distribution of the model drug released 
from an intravitreal implant, which was position near the hyloid membrane, at steady 
state [48].  The our MRI experimental data showed that the concentration of Gd-
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DTPA was 8.6 × 10-4 M at the other side of the vitreous about 10 hours post 
implantation in ex vivo, but it was 2.7 × 10-4 M about 7 hour post implantation in in 
vivo.  In our simulation study, estimated steady state concentration gradient of Gd-
DTPA from the implant to the other side of the vitreous was found to be stiffer in in 
vivo than in ex vivo because of elimination across the retina-choroid-sclera 
membrane.  Both the release rate and the position of the implants in the vitreous were 
found to affect the distribution of the therapeutic agents in the vitreous.  These are 
both important in delivering therapeutic agents within the desired clinical level to the 
target site. 
Other techniques are available for transport studies in tissue, such as 
fluoremtry and autoradiography, but these procedures have limitations such as being 
one-dimensional, requiring animal sacrifice followed by serial sectioning at various 
time points, and in some cases, being difficult to quantify.  Microdialysis has also 
been reported for analysis of vitreous drug concentrations in the eye.[42]  
One potential drawback to the MRI method is the limited availability of actual 
drug compounds with paramagnetic properties detectable by MRI.  Gd-DTPA 
(gadolinium diethylenetriaminepentaaceticacid) is a water soluble, MRI image 
enhancing agent with a molecular weight of approximately 958.  It was selected 
because its molecular weight is similar to drugs of interest in ophthalmologic 
delivery; it is water soluble; and it is a standard MRI enhancing agent which is 
approved for use in animals and humans.  Recently, larger varieties of compounds are 
becoming more available that are MRI contrast enhancing through chemical 
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Diffusion coefficient and permeability of Gd-DTPA in the vitreous and in the 
RCS membrane were determined to be 2.8 × 10-6 cm2/sec and 1.0 × 10-5 cm/sec, 
respectively by comparing simulation data to MRI experimental data.  Implantation 
site was found from simulation studies to be one of important factors at controlling 
















CHAPTER 5. Compartmental pharmacokinetic analysis of 
magnetic resonance imaging experimental data 
 
5.1 Objectives 
Compartmental pharmacokinetic studies will be performed to  
understand the movement of Gd-DTPA released from an intravitreal implant or a 
subconjunctival implant in the rabbit eyes. 
 
5.2 Introduction 
Development of efficient drug delivery methods requires an  
understanding of the distribution of applied drug in the eye. Pharmacokinetics is 
defined as the quantitative analysis of the processes of drug absorption, distribution, 
and elimination that determine the time course of drug action [43]. The previous 
studies described the distribution of therapeutic agents injected intravitreally or 
released from an ocular implant in the vitreous using the finite element mathematical 
eye models [4, 44-46, 120]. Even though the previous studies succeeded in predicting 
the spatial distribution and calculating the total amount of therapeutic agents in the 
vitreous at several time points, the mathematical models were complicated and 
several parameter values were demanded to run the model.   
Worakul et al. (1997) [40] summarized lumped pharmacokintic  
models depicting the distribution of ocular agents in the anterior segment of the eye. 
Several previous studies have been done to understand the elimination and the 
distribution of injected therapeutic agents in the vitreous using compartmental 
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pharmacokinetics [42, 122, 123]. To our knowledge, no lumped compartmental 
pharmacokinetic study has been performed to determine the elimination rate of 
therapeutic agents released from an ocular implant in the vitreous and the 
subconjunctival space.  
In this chapter, we calculate the elimination rate of MRI contrast agent, Gd- 
DTPA, released from both the intravitreal implant and the subconjunctival implant to 
determine the main elimination pathways in the rabbit eye with lumped compartment 
pharmacokinetic models. 
 
 5.3 Materials and methods 
5.3.1. Intravitreal implant MRI experiments 
In order to obtain estimates of the average Gd-DTPA clearance rates  
from the eye, a simplified, lumped two-compartment model of the eye was developed 
to perform a pharmacokinetic analysis. Figure 5-1 shows a schematic of the lumped 
model for intravitreal implant MRI experiment. Gd-DTPA is assumed to be cleared 
across the retina-choroid-sclera barrier (k1), transferred from the vitreous to the 
aqueous compartment across the hyloid membrane (k2), and eliminated from the 
aqueous compartment to some region that is outside the eye (k3). Drug is released into 
the vitreous compartment from the implant at a rate R. In vitro release rate of Gd-
DTPA from intravitreal implant was used for R. The mass balance equations 














23 +−=                              (5-2) 
where, Mv and Ma are amounts [mg] of Gd-DTPA in the vitreous and in the aqueous 
humor chamber, respectively. k1, k2, and k3 are transfer coefficients [hour-1] for the 
elimination pathways of Gd-DTPA.  
Experimental values for the total amount of Gd-DTPA in the vitreous and  
aqueous compartments at each time point were determined from the concentration 
MRI images of the eye by outlining the vitreous and aqueous regions of interest in all 
the image slices that constitute a particular eye. Each voxel concentration was then 
multiplied by the voxel volume and summed over all the slices that constitute 
particular region of interest, e.g. the vitreous or anterior compartment, at each time 
point. This analysis yielded data for the total Gd-DTPA amount, Mv and Ma, in the 
vitreous and aqueous compartments over time. Equations 5-1 and 5-2 were regressed 
against these data to determine the optimum values of the transfer coefficients with 













Figure 5-1. A schematic of the lumped two-compartment model of the eye for an 
intravitreal implant.  
k1: transfer coefficient across the retina-choroid-sclera barrier [hour-1]. 
k2: transfer coefficient from the vitreous to the aqueous humor compartment across 
the hyloid membrane [hour-1]. 
k3: transfer coefficient from the aqueous compartment to some region that is outside 
the eye [hour-1]. 
R: release rate from an intravitreal implant [mg/hour] 
MV: amount of Gd-DTPA in the vitreous [mg]. 







5.3.2. Subconjunctival implant MRI experiments 
A simplified, lumped three-compartment model of the eye was  
developed to analyze the ocular drug distribution from a subconjunctival implant at 
the equator in vivo. Figure 5-2 shows a schematic of the pharmacokinetic lumped 
model. In the subconjunctival implant experiment, Gd-DTPA is assumed to be 
transferred from the subconjunctival space directly into the aqueous humor (k1) and 
into the vitreous humor (k2), eliminated from the aqueous humor through Schlemm’s 
canal to the aqueous veins (k3) and from the vitreous into the aqueous humor (k4), and 
cleared from the subconjunctival space (i.e. movement into the episcleral veins and 
conjunctival lymphatics) (k5). Gd-DTPA is released into the subconjunctival space 
from the implant at a rate R(t). The mass balance equations for the subconjunctival 
implant experiment are: 
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where, Ma, Mv, and Ms are amount [mg] of Gd-DTPA in the aqueous humor, the 
vitreous, and the subconjunctival compartment, respectively. k1, k2, k3, k4, and k5 are 
transfer coefficients [hour-1] for elimination pathways of Gd-DTPA. Experimental 
values for the total amount of Gd-DTPA in the vitreous and aqueous compartments at 
each time points were determined and the above three equations were regressed by 
the same method as the case of intravitreal implant MRI experiment. The amount of 
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Figure 5-2. A schematic of the lumped two-compartment model of the eye for a 
subconjunctival implant.  
k1: transfer coefficient from the subconjunctival space directly into the aqueous 
humor. 
k2: transfer coefficient from the subconjunctival space directly into the vitreous 
humor. 
k3: transfer coefficient from the aqueous humor through Schlemm’s canal to the 
aqueous veins. 
k4: transfer coefficient from the vitreous into the aqueous humor. 
k5: transfer coefficient from the subconjunctival space (i.e. movement into the 
episcleral veins and conjunctival lymphatics). 





5.4.1. Intravitreal implant MRI experiments 
A lumped compartment, pharmacokinetic analysis (PK) of the Gd- 
DTPA distribution was performed as an adjunct to the finite element model. With the 
PK model, we were able to obtain overall average clearance parameters for the Gd-
DTPA elimination by the hypothesized major routes: (1) transport through the retina-
choroid-sclera membrane, (2) movement across the hyloid / cliary body region, and 
(3) washout by aqueous humor from the anterior chamber. The total amounts of Gd-
DTPA in the vitreous chamber and in the anterior aqueous humor chamber was 
determined from an analysis of the MRI concentration images as described in the 
Methods section. The experimental Gd-DTPA amounts in the vitreous chamber and 
in the anterior aqueous chamber are shown as the circles in Figures 5-3 and 5-4 
respectively. The two compartment pharmacokinetic model described in Figure 1, 
which utilized Equations (5-1) and (5-2), was used to obtain values of the clearance 
constants k1, k2, and k3 that optimized the fit between the simulation and experimental 
data by a regression method. The resultant values were k1 = 0.088 hour-1, k2 = 0.009 
hour-1, and k3 = 0.362 hour-1. Used these values in the model, the simulated amount of 
Gd-DTPA in the vitreous and aqueous humor are shown by the solid lines in Figure 
5-3 and 5-4. The amount of Gd-DTPA present in the anterior chamber is typically 40 
times less than that in the vitreous compartment. The amount of Gd-DTPA reaches a 
plateau at about 5 hour and then gradually clears from the vitreous. The in vitro 























Figure 5-3. Amount of Gd-DTPA released from an intravitreal implant in the vitreous 




























Figure 5-4. Amount of Gd-DTPA released from an intravitreal implant in the aqueous 










5.4.2. Subconjunctival implant MRI experiments 
We obtained information on the amount of Gd-DTPA in the vitreous and the  
aqueous humor, not in the subconjunctival space. Because of the shortage of 
information, we could the ratio between one another but not absolute transfer 
coefficient values. The experimental Gd-DTPA amounts in the vitreous chamber and 
in the anterior aqueous chamber are shown as the circles in Figure 5-5 and 5-6, 
respectively. The three compartment pharmacokinetic model descried in Figure 5-2 
the values of the transfer coefficients k1, k2, k3, k4, and k5 to be 0.0056 hour-1, 0.0076 
hour-1, 0.018 hour-1, 0.082 hour-1, and 4.73 hour-1, respectively.  Used these values in 
the model, the simulated amount of Gd-DTPA in the vitreous and aqueous humor are 
shown by the solid lines in Figures 5-5 and 5-6.  The amount of Gd-DTPA in the 
subconjunctival space was estimated from Equation (5-5) and shown in Figure 5-7.  
The amount of Gd-DTPA in the subconjunctival space peaked at the beginning 
because of the initial release burst in in vitro release rate and then decreased so fast 
from the subconjunctival space into the outside of the eye. The ratio of transfer 
coefficient from the subconjunctival space to the vitreous to that from the 
subconjunctival space to the aqueous humor was found to be 1.35. In this model, the 
Gd-DTPA transferred from the subconjunctival space to the vitreous was assumed to 
be eliminated into the aqueous humor because most of Gd-DTPA transferred from the 
subconjunctival space into the vitreous was observed near the hyloid membrane, not 
in the middle of the vitreous so that Gd-DTPA in the vitreous was assumed to be 





























Figure 5-5. Amount of Gd-DTPA released a subconjunctival implant in the aqueous 









































Figure 5-6. Amount of Gd-DTPA released from a subconjunctival implant in the 




























































  The two compartment pharmacokinetic PK model was a more simplified 
approach to quantitatively tracking the disposition of the Gd-DTPA in the vitreous 
and aqueous compartments than the finite element mathematical eye model 
mentioned in Chapter 4.  It is based on the amount of Gd-DTPA summed over the 
compartment volume and does not utilize spatial variations of amount.  In the lumped 
compartment pharmacokinetics for an intravitreal MRI experiment, the kinetic 
constants resulting from the best fit of the PK simulations to the summed 
experimental MRI amount data also showed a dominant elimination path of Gd-
DTPA to be via the retina-choroid-sclera barrier compared to the anterior elimination 
through the aqueous chamber. The PK kinetic constant for elimination through the 
retina-choroid-sclera (0.088 hour-1) was about 10 fold greater than that for elimination 
via the anterior aqueous path (0.009 hour-1). Comparison of these PK kinetic 
parameters to other relevant physiologic values or to equivalent finite element model 
parameters gave only modest agreement.  For example, the k3 parameter (0.362 hour-
1) in Figure 5-1 can be compared to the aqueous humor drainage in rabbits of 0.64 
hour-1, which is calculated as the aqueous humor production rate of 0.16 ml hour-1 [5] 
divided by the aqueous humor volume of 0.25 ml [125].  Also, the PK constant 
representing elimination through the retina-choroid-sclera barrier (k1) in Figure 5-1 
times the vitreous volume (V) can be compared to the finite element retina-choroid-
sclera permeability-area product (P×A), or in other words, k1 = P×A×V-1.  This 
P×A×V-1 product is (1.0 × 10-5 cm/sec) × (1.91 cm2) × (0.32 cm3)-1 = 0.21 hr-1 
compared to a k1 of 0.088 hr-1 in Figure 5-1.  There are a number of factors that may 
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relate to these discrepancies.  For example, to calculate drug fluxes, the Figure 5-1 
PK model utilizes the total amount of Gd-DTPA in compartments instead of the 
distributed amount in the finite element model.  Also, the values of the PK kinetic 
constants estimated from a best fit of Equations 5-1 and 5-2 to the averaged 
concentration data depend on the value assumed for the source term, R, in the PK 
model which represents the drug release rate.  The R term was based on the in vitro 
release studies. There may be differences between the in vitro and in vivo release 
rates.  Finally, errors in the calculation of the average Gd-DTPA concentrations used 
in the PK model can occur from incorrect estimates of the Gd-DTPA concentration 
from the MRI images at the extreme high and low concentrations values e.g. near the 
implant and in the aqueous compartment, respectively. In any event, both the finite 
element (Chapter 4) and the PK model suggest that Gd-DTPA is eliminated 
predominately through the retina-choroid-sclera barrier in the in vivo experiments.   
In lumped compartment pharmacokinetics for the subconjunctival implant  
MRI experiment, we found that Gd-DTPA was quickly eliminated from the 
subconjunctival space. However, we could not identify the pathway of Gd-DTPA 
elimination from the subconjunctival space, but collectively, in Figure 5-2 these 
pathways have an elimination coefficient (k5) 3-log units higher than that for particle 
movement into the vitreous (k2). This Figure 5-2 PK study found that delivering 
therapeutic agents from the subconjunctival space into the inside of the eye was 
inefficient because of active elimination mechanism such as the choroidal blood flow. 
In Chapter 2, lipophilic therapeutic agent, H-110, released from a subconjunctival 
implant could not be delivered to the subretinal space across the choroid. From the 
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subconjunctival H-110 study and the subconjunctival Gd-DTPA study, we concluded 
the choroidal blood flow is a formidable barrier to the low molecular weight 
therapeutics from the subconjunctival space into the subretinal space. 
In the MRI images, we could not determine the amount of Gd-DTPA in the  
subconjunctival space because the difference between the subconjunctival space and 
the standard solution.  No information on the amount of Gd-DTPA in the 
subconjunctival space prevented the determination of the absolute value.  Only 
relative values showing the ratio of one elimination rate constant to another could be 
determined. 
Pharmacokinetic studies with lumped compartments gave useful information  
on the fate of the drugs and is important in determining an efficient delivery route of 




Elimination of Gd-DTPA released from an intravitreal implant from the 
 vitreous was found from the two-compartment pharmacokinetic study to be about 10 
times greater than transport from the vitreous to the aqueous humor.  Elimination of 
Gd-DTPA from the subconjunctival space to external of the eye was determined from 
the three-compartment pharmacokinetic study to be about 1000 times more dominant 







CHAPTER 6. Pharmacokinetic study of traimcinolone 
acetonide injected intravitreally. 
 
6.1 Objectives 
A pharmacokinetic model will be developed to analyze triamcinolone  
acetonide experimental data and decide optimal injection doses in human cases. 
 
6.2 Introduction 
Intravitreal administration of triamcinolone acetonide has been used widely in  
ophthalmology for the treatment of diabetic retinopathy [19, 70], uveitis [126-129], 
pseudophakic cystoid macular edema [130, 131], choroidal neovascularization 
associated with AMD [9, 67-69], and macular edema associated with central retinal 
vein occlusion [71-73].   
To maximize the benefits of intravitreal injected triamcinolone acetonide to  
the posterior segment eye diseases, it would be desirable to determine the length of 
time that therapeutic levels are maintained.  Up to now, several pharmacokinetic 
studies have been done on the clearance following intravitreal injection of a single 
dose triamcinolone acetonide [132-134].  However, these studies do not permit 
estimation of clearance for other doses.  In addition, the studies do not provide the 
basis for estimating the optimal dosing for clinical efficacy.   
The purpose of this study was to aid in optimizing the administration of  
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triamcinolone acetonide by developing a guide for predicting the clearance in patients 
over a range of doses from pharmacokinetic studies in rabbits.       
 
6.3 Materials and methods 
6.3.1 TAC-PF formulation 
Triamcinolone acetonide USP grade (Voight Global Distribution,  
LLC, Kansas City, MO) was prepared as a sterile 40 mg/ml or 160 mg/ml suspension 
in normal saline for injection USP (B. Braun Medical Inc., Irvine, Ca) in single use 
vials by the Clinical Center Pharmacy Department at the National Institutes of Health.  
Hydroxypropylmethylcellulose 0.5% USP was added to increase the viscosity of the 
formulation and enable the drug particles to stay in suspension for a minimum of 20 
minutes after shaking allowing time to draw an accurate dose.  
 
6.3.2 Intravitreal TAC-PF animal experiment 
Fifty-two New Zealand White rabbits of either sex weighing 2-3 kg  
 
were used (Covance Laboratories, Inc., Vienna, VA) and the procedures adhered to 
the guidelines from the Association for Research in Vision and Ophthalmology for 
animal use in research. Food and water were supplied to the rabbits ad libitum.  
Animals were anesthetized with ketamine hydrochloride (Fort Dodge, Inc., Fort 
Dodge, Indiana) 35mg/kg IM, xylazine (Phoenix Scientific, Inc., St. Joseph, MO) 
5mg/kg IM, and proparacaine 1% ophthalmic drops (Allergan America, Hormigueros, 
PR) were used topically on the right eye.  After adequate anesthesia and akinesia 
were obtained, a lid speculum was placed and the right eye was injected 3 mm behind 
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the surgical limbus in the superotemporal quadrant with 0.1 ml (4 mg or 16 mg) 
TAC-PF.  Rabbits were euthanized with a pentobarbital overdose (Beuthanasia-D 
Special, Schering-Plough Animal Health Corp., Kenilworth, NJ) at intervals of 1 
hour, 7 days, 14 days, 28 days, 42 days, 56 days, and 119 days for the 4 mg injection 
or 1 hour, 7 days, 27 days, 70 days, 131 days, and 238 days for the 16 mg injection.  
The eyes were enucleated and immediately frozen at –70˚ C for later dissection and 
drug extraction.  
    The eyes were dissected while frozen by first removing the cornea with a 
razor blade and the aqueous humor, ciliary body/ iris, lens, and vitreous were isolated.  
A 5 × 5 mm section of sclera/choroid and retina was removed en bloc adjacent to the 
optic nerve.  The TA was extracted from the tissues by the addition of sufficient 
amount of HPLC grade acetonitrile to dissolve the remain TA (Burdick & Jackson, 
Inc., Muskegon, MI) and then the TA-acetonitrile solution was sonicated with a 
model GEX 600 Ultrasonic processor (Thomas Scientific, Swedesboro, NJ) set at 
level 3.5 for 1 minute for aqueous and vitreous humor.  The samples were incubated 
for 24 hours at room temperature and spun down in a GS-6R centrifuge (Beckman 
Coulter Inc., Fullerton, CA) for 30 minutes at 8,000 rpm and the supernatants were 
submitted for HPLC analysis.  The drug assays were performed using a Hewlett 
Packard HP1100 HPLC system (Agilent Technologies, Palo Alto, CA) equipped with 
a Diode Array detector, an auto-sampler, a quaternary, and an HP Kayak workstation 
which controlled the operation of HPLC and analyzed the data.  A Beckman 
Ultrasphere C-18 column (5 µm, 250 × 4.6 mm)(Beckman Coulter, Inc., Fullerton 
CA) was used for separation and the wavelength for detection was set at 254 nm.  The 
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flow rate employed was 1.0 ml/min with a mobile phase of 60% of water and 40% of 
acetonitrile by volume.  The retention time of TAAC was 7.0 minutes and the TAAC 
detection limit was 10 ng/ml. 
 
6.3.3 Pharmacokinetics of TAC-PF in the vitreous 
On the assumption that the elimination rate at any specific time  
depends on amount in the combined vitreous and depot, the experimental data were 
regressed with the following equation: 
                                               nMk
dt
dM
×−=                                          (6-1) 
where, t [day] is time in days and  M [mg] represents the amount of triamcinolone 
acetonide in the depot plus the vitreous.  k [day-1] is an elimination rate constant. n is 
a constant to characterize the nonlinear dependence of clearance on the dose of 
triamcinolone acetonide. The elimination rate constants for 4 mg injection and 16 mg 
injection, k4 and k16, and n value in Equation (6-1) were found by regressing animal 
experimental data of 4 mg injection and 16 mg injection simultaneously using 
MATLAB Optimization toolbox (version 2.3, The MathWorks, Inc., Natick, MA, 
USA). 
The ratio of the elimination rate constants was determined with the following  
relationship (See Appendix I): 

















                                  (6-2) 
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From the calculated k4, k16, and doses, Dose4 = 4 mg and Dose16 = 16 mg, a value for 
m value was determined.  The above Equation (6-2) allowed estimating the 
elimination for other intravitreal triamcinolone acetonide doses. 
A half-life of intravitreal injected triamcinolone acetonide was calculated  
with the following equation (See Appendix II): 











t                  (6-3) 
6.4 Results 
Triamcinolone acetonide, is a lipophilic corticosteroid. It forms a  
depot in the vitreous when injected intravitreally (Figure 6-1).  In Figure 6-1, the 
white spot represents the depot of triamcinolone acetonide in the vitreous. 
 
 
Figure 6-1. TAC-PF depot in the rabbit vitreous 1 day post implantation. A white spot 





In the experiment, a small amount of injected triamcinolone acetonide  
was observed to leak back through an injection needle hole.  It was difficult to 
estimate the small leakage and so we could not confirm that exactly 4 mg or 16 mg 
triamcinolone acetonide was injected.   
The amount of triamcinolone acetonide extracted from the vitreous at  
each time point is shown in Figure 6-2 (4-mg intravitreal injection) and Figure 6-3 
(16-mg intravitreal injection).  The data from 4 mg (k4) and 16 mg (k16) triamcinolone 
acetonide injections were regressed with the Equation (6-1) to find the elimination 
rate constants k4 and k16, and the exponent n.  The resulting values were k4=0.0245 
[day-1], k16=0.0069 [day-1], and n=1.41.  The regression curves are shown as solid 
lines in Figure 6-2 and Figure 6-3.  The elimination of water-soluble drugs from the 
vitreous follows linear one-compartment pharmacokinetic behavior with a value in 
Equation (6-1) of n=1. Because poorly soluble intravitreal injected triamcinolone 
acetonide sediments to from a depot, the drug is not distributed homogenously in the 
vitreous. 
Using the k4 and k16 values determined by regressing by Equation 6-1  
was found that m=-0.91 from Equation (6-2).  Using Equation (6-2) to extrapolate to 
other doses, we predict rate constant values for 1-mg and 8-mg dose injections, k1 and 
k8 to be 0.087 [day –1] and 0.013 [day-1], respectively.  Using the estimated k1 and k8 
values and Equation (6-1) allowed us to predict the time course of intravitreal injected 
TA in the vitreous for doses of 1 mg injection and 8 mg (Figure 6-4). 
The half-life of each intravitreal injection dose was calculated with  
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Equation (6-3) and was found to follow the following relationship with injection dose 
(Figure 6-5): 
Half-life [days] = 9.20 × Injection amount [mg] 0.508 
Results of this pharmacokinetic study are summarized at Table 6-1. 
 




Mass transfer coefficient (k) [day-1] 
Half-life [days] 
1 mg 0.0870 9.2 
4 mg 0.0245 18.6 
8 mg 0.0130 26.5 




























Figure 6-2. 4 mg TA intravitreal injection experimental data (dots) and regression 
















Figure 6-3. 16 mg TA intravitreal injection experimental data (dots) and regression 


























Figure 6-4. Estimated amount of TA in the vitreous in 1 mg injection (solid line) and 
















Figure 6-5. The relationship between the calculated half-life of TA in the vitreous and 




















Diseases affecting the posterior segment of the eye, age-related  
macular degeneration (AMD) and diabetic retinopathy, are the main causes of 
blindness in developed countries.  Although topical administration such as eye drop 
accounts for nearly 90% of the currently accessible market formulations for drug 
application [15], less than 5% of topically applied therapeutic agent passes through 
the cornea because of tear flow drainage, dilution by blinking, corneal diffusion 
resistance, and aqueous humor washout [15, 16, 44].  Systemic administration of 
biologically active agents often fails to deliver to some target sites at therapeutic 
levels because of the blood-retina barrier and the blood-aqueous barrier [1].  For 
effective treatment, large systemic doses are often required, which can cause systemic 
adverse effects.  Therefore, intravitreal injection is a current method being used to 
deliver drugs directly to the posterior segment of the eye [70, 71].  However, one of 
disadvantages of intravitreal injection is rapid elimination from the vitreous [46].  
Schindler RH et al. [132] reported that cortisone was washed out of the eye within 
approximately 24 hours after a single intravitreal injection.  To prolong the duration 
of intravitreal injected triamcinolone acetonide, the use of the crystalline form of 
triamcinolone acetonide, which formed a depot in the vitreous (Figure 6-1), was 
suggested [135].   When crystalline triamcinolone acetonide was injected into the 
vitreous, it condensed into a small region to form a depot because of rapid diffusion 
of the saline vehicle from the suspension and lipophilicity of triamcinolone acetonide 
[132].  Jonas JB [136] detected triamcinolone acetonide in the human aqueous humor 
up to 6 months after 25 mg intravitreal instillation.  Scholes GN et al. [133] 
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determined the half-life of 0.4 mg intravitreal injected triamcinolone acetonide to be 
1.6 days in rabbit eyes and detected 66 ± 19 µg in the rabbit vitreous with HPLC 13 
days post injection.  The authors clinically observed triamcinolone acetonide depot in 
the vitreous by indirect ophthalmoscopy up to average 23.3 days after 0.4 mg 
intravitreal injection.  Following intravitreal injection of 0.5 mg triamcinolone 
acetonide [132], 6.5 days average retention of the drug in eyes that underwent a 
combined vitrectomy and lensectomy, 16.8 days average retention in eyes that 
underwent vitrectomy only, and 41 days average retention in normal rabbit eyes was 
reported, which meant clearance of triamcinolone acetonide from the vitreous 
depends on ocular condition.  In our experiment, we could clearly observe a white 
triamcinolone acetonide depot in all of isolated frozen vitreous (n=4) 56 days post 4-
mg triamcinolone acetonide injection and 131 days post 16-mg triamcinolone 
acetonide injection; however, in two of four isolated frozen vitreous 119 days post 4-
mg injection and two of four isolated frozen vitreous 238 days post 16-mg injection.   
All of triamcinolone acetonide injected rabbit eyes were found to contain HPLC 
detectable amount in the vitreous by 119 days post 4-mg injection and 238 days post 
16-mg injection. 
It is important to know for clinical use how long after a single intravitreal  
injection the concentration of triamcinolone acetonide in the vitreous remains above 
the therapeutic index.  In our experimental data analysis, the elimination rate of 
triamcinolone acetonide (dM/dt) was found to depend on the amount of triamcinolone 
acetonide in the vitreous raised to the power, n=1.41 (M1.41) because triamcinolone 
acetonide did not distribute homogenously in the vitreous but formed a depot.  Since 
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we could not use our previous ocular pharmacokinetic studies in rabbit [41] to 
calculate half-life of each injection, a unique pharmacokinetic analysis was developed 
to characterize the clearance from the vitreous of depot formulation for steroid types 
of drugs.  Assuming that all of administered drug will be eliminated after five half-
lives, it was estimated that 4 mg or 16 mg intravitreal injected triamcinolone 
acetonide should be for 93 days or 188 days, respectively.  To keep within detectable 
amount of triamcinolone acetonide for one year with two times injections in rabbit 
eyes, doses of 16 mg triamcinolone acetonide are required. 
Determination of the elimination pathways for intravitreal injected drugs is  
important.  Intravitreal injected ocular therapeutics are thought to be eliminated either 
across the retinal surface or via drainage out of the anterior chamber depending on 
solubility [46].  Most intravitreal injected hydrophilic agents or hydrophobic agents 
were concluded to be eliminated via the annular gap between the lens and the ciliary 
body or through the retina-choroid-scleral membrane, respectively [40].   In our 
experiment, a triamcinolone acetonide depot was observed to position in the posterior 
vitreous near the retina and no triamcinolone acetonide was detected in the harvested 
aqueous humor.  This suggests that the major route of elimination for traimcinolone 
acetonide is across the retina barrier in the rabbit eye.  In a previous study [134], 
triamcinolone acetonide concentrations in human aqueous humor of 2.2 – 7.2 µg/ml 
were measured following 4-mg intravitreal injection.  The authors concluded 
intravitreal injected traimcinolone acetonide was eliminated mainly via the anterior 
route.   These discrepancies are related to several factors.  There are a number of 
differences in the anatomy and physiology of the rabbit eye. The choroidal vessel 
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permeability and flow is different in rabbits compared with primates [82, 101, 102].  
For example, the choroidal flow is 16% higher in rabbits compared with monkeys, 
which may increase elimination of triamcinolone acetonide across the retina in rabbit 
[103, 104].  The previous study [134] has been done in the eyes of elderly patient 
whose vitreous is often liquefied.  Liquefied vitreous humor circulates by convection 
and the ocular globe movement and helps dissolve the triamcinolone acetonide crystal 
faster and disperse more easily into the anterior chamber than in normal eyes.  
However, considering the high partition coefficient of lipophilic agents into the cell 
membranes of the retina and the very low aqueous solubility of triamcinolone 
acetonide, it is doubtful that a major elimination of intravitreal injection 
triamcinolone acetonide is via the anterior route. 
The elimination of intravitreal triamcinolone acetonide can be considered to  
involve three steps; dissolution from a depot into the vitreous, diffusion in the 
vitreous, and elimination across the retina.  The rate of clearance across the retina is 
assumed to be proportional to the vitreal concentration of dissolved drug at interface 
with the retina.  The elimination rate constant for this step is, kR = P×A×V-1 in which 
V = 1.5 ml is the volume of the rabbit vitreous [41], A is the superficial surface area 
of the vitreous-retina interface, 1.22 cm2 [120] and P is apparent permeability of the 
blood-retinal barrier corresponding to this area.  Friedrich has estimated the range of 
permeability value to be of the order of 10-7 to 10-4 cm2/sec [47].  The lower limit 
corresponds to hydrophilic solutes that are poorly permeable.  As a lipophilic solute, 
triamcinolone acetonide would likely be associated with a high permeability value.  
The upper limit on the rate constant is kR = (1.0×10-4 cm/sec)×(1.22 cm2)×(1.5 cm3)-1 
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= 7.03 [day-1].  The diffusion rate of triamcinolone acetonide in the vitreous can be 
characterized by the following parameter, kD = D/r2, where D is diffusion coefficient 
in the vitreous and r is the radius of the rabbit vitreous.  For triamcinolone acetonide 
with a molecular weight of 434.5 Da, the diffusion coefficient is estimated to be 
5.6×10-6 [cm2/sec] [47].  For r = 0.72 cm [120], the diffusion rate constant of 
triamcinolone acetonide in the vitreous, kD, was calculated to be 0.9 [day-1].  The 
dissolution rate of triamcinolone acetonide from a depot into the vitreous, kS can be 
calculated from the following equation:  
                                                     RDS kkkk
1111
++=  
where, k  represents the overall rate constant for elimination from the eye. In the case 
of 4 mg or 16 mg triamcinolone acetonide intravitreal injection, dissolution rate into 
the vitreous, kD, was calculated to be 0.0253 or 0.0070 [day-1].  In comparison to the 
rate constant for diffusion in the vitreous and permeation across the retina, the 
dissolution from a depot into the vitreous was found to be the slowest step in the 
elimination of triamcinolone acetonide from the eye.  The overall rate of elimination 
was found to depend upon the amount of triamcinolone acetonide injected.  This 
result suggests that the rate of elimination is independent of the vitreous volume.  
This conclusion is supported by the previous study [134] who measured the half-life 
of 4-mg intravitreal injected triamcinolone acetonide in the human vitreous to be 18.6 





The empirical pharmacokinetic equations were developed and used to analyze  
triamcinolone acetonide intravitreal injection animal experimental data.  It was 
determined that animal experimental data about intravitreally injected triamcinolone 
acetonide forming a depot in the vitreous can be applied to human cases with 
ignorable error because the elimination limiting step of triamcinolone acetonide from 
the vitreous is the dissolution from the depot into the vitreous.  16 mg intravitreal 
injection of triamcinolone acetonide was found to be required to keep the therapeutic 

















CHAPTER 7. Summary and recommendations 
7.1 Summary 
The movement of drug surrogates, H-110 (small size and lipophilic)  
and Gd-DTPA (small size and hydrophilic) released from sustained release implants 
in the eye was studied with fluorescent and MRI. 
Using the fluorescent technology, the movement of H-110 in the tissue  
level could be analyzed only qualitatively.  On the other hand, we could analyze the 
movement of MRI contrast agent, Gd-DTPA in the vitreous quantitatively by 
referring to concentration calibration standards as well as qualitatively.  However, we 
could not accurately determine the distribution of Gd-DTPA within the finer structure 
of some tissues such as the retina because of the MRI detection limitation and 
resolution with the current MR setup. 
In the intravitreal H-110 study, H-110 released from a HPMC based  
implant reached the outer plexiform cell layer by 3 hour post implantation and the 
subretinal region 1 day post implantation most likely by diffusion.  In the 
subconjunctival H-110 study, some H-110 released from an implant could be detected 
at the subretinal space 3 day post implantation.  It is felt that H-110 can be eliminated 
by uptake into the choroidal blood flow.  H-110 was observed to distribute 
circumferentially around the sclera, the conjunctiva, and then to the cornea.  From 
this study, we conclude that lipophilic and low molecular weight therapeutics (H-110) 
can be delivered more efficiently from the vitreous into the subretinal space than from 
the subconjunctival space into the subretinal space because of enhanced retina 
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transport of lipophilic material and because of elimination by the choroidal blood 
flow. 
In the in vivo MRI experiment with a subconjunctival implant, some  
Gd-DTPA could be detected in the aqueous humor and the anterior vitreous.  A large 
portion of the released Gd-DTPA is thought to be eliminated through the episcleral 
and conjunctival venous blood flow, conjunctival lymphatic drainage, choroidal 
blood flow, and the episcleral veins as reported in literatures.  A high concentration of 
Gd-DTPA was detected in the buccal lymph node in our study (Figure 3-7).  
However, we could not detect Gd-DTPA in the choroid because of resolution limits 
and the rapid dilution of Gd-DTPA through the choroid. According to our three-
compartment pharmacokinetic model, Eliminating Gd-DTPA from the 
subconjunctival space was 100 times faster than transferring into the vitreous or the 
aqueous humor. 
In the in vivo intravitreal MRI experiment, we found that a  
concentration gradient was established from the back of the lens to the posterior 
retina.  In contrast, in the intravitreal ex vivo MRI experiment, a concentration 
gradient did not exist within the vitreous.  We believe that this is due to the diffusion 
of Gd-DTPA across the retina and then elimination by choroidal blood flow in the in 
vivo case, but is not present in the ex vivo case.  The permeability of Gd-DTPA 
through the retina-choroid-sclera membrane was calculated to be 1.0 × 10-5 cm/sec 
based on the MRI experimental data and the computer simulation data.  The diffusion 
coefficient of Gd-DTPA in the vitreous was determined to be 2.8 × 10-6 cm2/sec, 
which is in agreement with the previous studies.   
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In the intravitreal MRI two-compartment pharmacokinetic study,  
released Gd-DTPA was eliminated 10 times faster across the retina than through the 
aqueous humor flow.  Because of the elimination mechanism of Gd-DTPA from the 
vitreous, which results in a concentration gradient from the near implant region to the 
more distal region in the vitreous at steady state, implantation position in the vitreous 
in controlling the concentration of therapeutics at the target site is of prime 
importance. 
From the H-110 fluorescent experiment and the Gd-DTPA experiment,  
we found that delivering both small size hydrophilic and small size lipophilic agents 
from the subconjunctival space into the subretinal space was less efficient than 
delivering from the vitreous to the subretinal space because of several barrier 
mechanisms.   
A pharmacokinetic study was performed to calculate the half-life of a  
preservative-free formulation of triamcinolone acetonide (TAC-PF) in the New 
Zealand White rabbit to determine an injection schedule in human clinical trials.  In 
indirect ophthalmoscopic study, it was observed that intravitreally injected 
triamcinolone acetonide did not disperse in the vitreous homogeneously, but formed a 
depot.  Several previous compartmental pharmacokinetic analyses have been 
developed with an assumption that an applied agent distributes homogenously within 
the vitreous compartment.  Our pharmacokinetics was unique in that it accounted for 
the depot effect.  In the animal studies, we found the half-lives of 4 mg and 16 mg 
intravitreal injections to be 18.6 days and 37.6 days, respectively.  With this animal 
experimental data and our mathematical analysis for microparticulated steroid 
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therapeutics, the half-lives of 1 mg and 8 mg intravitreal injections were estimated to 
be 9.2 days and 26.5 days, respectively.   With the above calculated half-life data, the 
relationshiop between amount of TAC-PF injection and half-life in the vitreous was 
found to follow the following relationship: 
                  (Half-life[days]) = 9.2 × (Amount of injected TAC-PF [mg])0.508  
In this study, we determined that the rate-limiting step for elimination of 
triamcinolone acetonide was dissolution from the depot into the vitreous and not the 
diffusion in the vitreous or elimination across the retina. 
 
7.2 Recommendations for future research 
In this study, we determined the movement of small size drug  
surrogates, H-110 (lipophilic) and Gd-DTPA (hydrophilic), delivered by sustained 
release implants in the eye.  Several macromolecular anti-angiogenic agents such as 
vascular endothelial growth factor (VEGF) receptor chimeric protein, tissue inhibitor 
of metalloproteinase (TIMP)-1 (28 kDa), TIMP-2 (24 kDa), pigment epithelium-
derived factor (50 kDa) have been tested in the clinics for treating ocular disorders of 
the posterior segment of the eye [63].  However, more information about the 
movement of macromolecular compounds in the eye is needed since it is important to 
develop unique delivery method and to control the concentration at the target site.  
Because of the improvement of labeling technology, Gd-DTPA can be conjugated to 
macromolecular materials such as lysozyme (14.3 kDa), trypsinogen (24 kDa), 
ovalbumin (45 kDa), and bovine serum albumin (67 kDa).  The movement of 
macromolecular compounds has been studied in cartilage [137].  IgG antibody was 
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conjugated with Gd or Mn and the relxation properties were tested to confirm that the 
conjugated compounds were reasonable for MRI study [138]. To my knowledge, no 
MRI study has yet been done in the eye with macromolecules labeled with 
paramagnetic metal.  Investigation to understand the movement of macromolecules 
released from sustained release implants in the eye using the MRI is one 
recommendation for future work. By comparing the movement of small size materials 
with macromolecules, the effect of molecular size on the movement of agents in the 
eye will be confirmed. 
Our mathematical eye model consisted of only the lens, the vitreous,  
and the posterior segment of the eye (the retina-choroid-sclera membrane).  In this 
study, the mathematical model did not include certain anterior segments of the eye 
such as the posterior segment of the aqueous humor, the anterior segment of the 
aqueous humor, and the cornea.  In addition, the retina, the choroid, and the sclera 
were simplified in the current model into only one lumped region because of limited 
information about each membrane.  Future work can be aimed at improving and 
extending the mathematical model to add an anterior chamber and to separate the 
posterior region into sclera, choroid, and retina.  Such an improved model will allow 
for simulations of subconjunctival delivery of drugs with prediction of drug 
concentrations in each subconjunctival tissue. 
Nowadays, both microparticles and nanoparticles have been  
intensively studied to deliver ocular therapeutics for an extended time period without 
complicated surgery.  A previous study represented the movement of flucorescent 
conjugated nanoparticles injected intravitreally in the eye, rather than drugs released 
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from the particles [139].  Average particle size of our TAC-PF was 4 µm (not 
reported in this dissertation). However, triamcinolone acetonide dissolved, not 
released into the vitreous. In addition, the TAC-PF formed a depot in the vitreous, not 
dispersed. It is difficult to apply the pharmacokinetics of TAC-PF to biodegradable 
microparticles or nanoparticles cases. To determine the movement of microparticles 
or nanoparticles injected intravitreally or subconjunctivally, further pharmacokinetic 
















































With the assumption that the limiting step for clearance of triamcinolone  
acetonide from a depot into the vitreous is dissolution, the elimination rate can be 
expressed with the following equation: 
                                                 0CAPdt
dMr ××−==                             (I-1) 
where, P, A, and C0 denote the permeability, the surface area of a depot, and the 
concentration of dissolved triamcinolone acetonide in the aqueous phase within the 
depot,  respectively.   
In addition, the surface area of depot is assumed to be proportional to the 
amount  
of triamcinolone acetonide in a depot: 
                                                  A = K×Mn                                                  (I-2) 
where, K is a proportional constant.  In sheet geometry and a spherical geometry, n 
must be 0 and 2/3, respectively. 
Substituting (I-2) into (I-1) gives for the   
4-mg injection 
                                
nMk
dt
dMr ×−== 44   where k4 = P×C0×K4                (I-3) 
and for the 16-mg injection 
                                
nMk
dt
dMr ×−== 1616   where k16 = P×C0×K16           (I-4) 
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Assuming the area coefficients, in turn, depend upon the initial mass of the 
depot  
to a power m, K=L×Mim, leads to  
                                    k4 = P × C0 × L × M4m                                  (I-5) 
                                    k16 = P × C0 × L × M16m                                (I-6) 
Taking the rates of (I-5) to (I-6) gives, 
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The elimination of triamcinolone acetonide from the vitreous is governed by the 
following equation: 
                                  nMk
dt
dM
×−=                                           (II-1) 
By multiplying both sides with , the equation (1) is written by the following 
equation, again. 
dtM n ×−
                               dtkdM
M n
×−=
1                                         (II-2) 
To calculate half-life of triamcinolone acetonide in the vitreous, the both sides of 
Equation (II-2) was integrated. 










dtkdM ∫                          (II-3) 
where, M and M0 represent amount at a specific time and an initial time, respectively. 
t1/2 means the time when amount of injected triamcinolone acetonide becomes to be 
half. 
Finally, Equation (II-3) can be simplified to be as follows: 
































t                     (II-4) 
Equation (II-4) shows that half-life depends on both the elimination rate 
constant  
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